

AUDITED FINANCIAL STATEMENTS,
SUPPLEMENTARY INFORMATION, AND REPORTS AND
SCHEDULES REQUIRED BY THE UNIFORM GUIDANCE

Baylor College of Medicine
Years Ended June 30, 2021 and 2020
With Reports of Independent Auditors

Ernst & Young LLP



Baylor College of Medicine

Audited Financial Statements, Supplementary Information, and Reports
and Schedules Required by the Uniform Guidance

Years Ended June 30, 2021 and 2020

Contents

Report of Independent Auditors.....1

Audited Financial Statements

Consolidated Balance Sheets3

Consolidated Statements of Activities4

Consolidated Statements of Cash Flows.....5

Notes to Consolidated Financial Statements.....7

Supplementary Information

Financial Responsibility Supplemental Schedule.....51

Reports and Schedules Required by the Uniform Guidance

Report of Independent Auditors on Internal Control Over Financial Reporting and
on Compliance and Other Matters Based on an Audit of Financial Statements
Performed in Accordance With *Government Auditing Standards*.....54

Report of Independent Auditors on Compliance for Each Major Federal Program and
Report on Internal Control Over Compliance Required by the Uniform Guidance.....56

Schedule of Expenditures of Federal Awards.....60

Notes to Schedule of Expenditures of Federal Awards97

Schedule of Findings and Questioned Costs.....100



Ernst & Young LLP
1401 McKinney Street
Suite 2400
Houston, TX 77010

Tel: +1 713 750 1500
Fax: +1 713 750 1501
ey.com

Report of Independent Auditors

The Management and The Board of Trustees
Baylor College of Medicine

Report on the Financial Statements

We have audited the accompanying consolidated financial statements of Baylor College of Medicine, which comprise the consolidated balance sheets as of June 30, 2021 and 2020, and the related consolidated statements of activities, and cash flows for the years then ended and the related notes to the financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in conformity with U.S. generally accepted accounting principles; this includes the design, implementation and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free of material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these consolidated financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion


In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of the Baylor College of Medicine as of June 30, 2021 and 2020, and the changes in its net assets and its cash flows for the years then ended in conformity with U.S. generally accepted accounting principles.

Supplementary Information

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. We have not performed any procedures with respect to the audited consolidated financial statements subsequent to October 15, 2021. The accompanying Schedule of Federal Awards as required by Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* is presented for purposes of additional analysis and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States. In our opinion, the information is fairly stated, in all material respects, in relation to the consolidated financial statements as a whole.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we also have issued our report dated October 15, 2021 on our consideration of the Baylor College of Medicine's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Baylor College of Medicine's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering Baylor College of Medicine's internal control over financial reporting and compliance.



October 15, 2021, except for our report on the Schedule of Expenditures of Federal Awards, for which the date is July 18, 2022

Baylor College of Medicine
Consolidated Balance Sheets

	June 30	
	2021	2020
	<i>(In Thousands)</i>	
Assets		
Cash and cash equivalents	\$ 44,277	\$ 29,241
Accounts receivable, net:		
Patient	27,578	24,468
Affiliates	111,498	112,512
Grants and contracts, and others	120,087	98,384
Pledges receivable	42,084	43,826
Notes receivable	17,389	17,866
Investments, including securities loaned of \$98,756 and \$17,089 for 2021 and 2020, respectively	1,689,478	1,224,606
Equity investments in unconsolidated affiliates	321,471	320,393
Security lending collateral	108,711	17,701
Property and equipment, net	389,727	403,992
Leased right-of-use assets – operating	95,353	105,370
Other assets	18,781	14,484
Total assets	\$ 2,986,434	\$ 2,412,843
Liabilities and net assets		
Liabilities:		
Accounts payable and other liabilities	\$ 233,216	\$ 191,675
Short-term line of credit	–	45,000
Interest rate swap liability, net	85,258	105,029
Lease liability – operating	96,712	105,978
Self-insurance reserves	45,956	38,879
Deferred revenue	137,393	112,989
Bonds and notes payable	592,994	586,695
Assets held on behalf of others	53,105	42,106
Payable under security lending agreements	108,711	17,701
Total liabilities	1,353,345	1,246,052
Net assets:		
Without donor restrictions	491,208	358,776
With donor restrictions	1,141,881	808,015
Total net assets	1,633,089	1,166,791
Total liabilities and net assets	\$ 2,986,434	\$ 2,412,843

See accompanying notes.

Baylor College of Medicine

Consolidated Statements of Activities

	Year Ended June 30, 2021			Year Ended June 30, 2020		
	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total
	<i>(In Thousands)</i>			<i>(In Thousands)</i>		
Operating revenues						
Tuition and fees, net	\$ 23,814	\$ –	\$ 23,814	\$ 23,459	\$ –	\$ 23,459
Medical services, net	306,635	–	306,635	293,754	–	293,754
Affiliated hospital contracts	1,078,255	–	1,078,255	1,051,860	–	1,051,860
Government grants and contracts:						
Direct	335,558	–	335,558	294,333	–	294,333
Indirect	90,768	–	90,768	83,562	–	83,562
Private grants and contracts:						
Direct	77,359	–	77,359	79,396	–	79,396
Indirect	10,623	–	10,623	9,474	–	9,474
Gifts and pledges	4,909	–	4,909	5,025	–	5,025
State appropriations	46,435	–	46,435	26,110	–	26,110
Investment income, net of expenses	58,183	–	58,183	58,586	–	58,586
Equity in gain (loss) of unconsolidated affiliates – operating	3,077	–	3,077	(18,410)	–	(18,410)
Equipment acquired through grants and contracts	11,273	–	11,273	9,668	–	9,668
Net assets released from restrictions	22,668	–	22,668	32,818	–	32,818
Other	82,801	–	82,801	117,248	–	117,248
Total operating revenues	2,152,358	–	2,152,358	2,066,883	–	2,066,883
Operating expenses						
Salaries, wages, and benefits	1,661,966	–	1,661,966	1,615,182	–	1,615,182
Services, supplies, and other	408,311	–	408,311	396,364	–	396,364
Depreciation	55,775	–	55,775	56,559	–	56,559
Interest	24,860	–	24,860	27,058	–	27,058
Total operating expenses	2,150,912	–	2,150,912	2,095,163	–	2,095,163
Operating revenues in excess (deficit) of expenses	1,446	–	1,446	(28,280)	–	(28,280)
Nonoperating activities						
Gifts and pledges	671	41,438	42,109	205	12,888	13,093
Investment income (loss), net of distribution and expenses	118,780	315,096	433,876	(5,533)	(110,555)	(116,088)
Unrealized gain (loss) on interest rate swaps	20,751	–	20,751	(33,236)	–	(33,236)
Net assets released from restrictions	–	(22,668)	(22,668)	–	(32,818)	(32,818)
Equity in gain (loss) of unconsolidated affiliates – nonoperating	1,798	–	1,798	(8,460)	–	(8,460)
Other nonoperating activities	(11,014)	–	(11,015)	(771)	–	(771)
Change in net assets from nonoperating activities	130,986	333,866	464,852	(47,795)	(130,485)	(178,280)
Change in net assets	132,432	333,866	466,298	(76,075)	(130,485)	(206,560)
Net assets, beginning of year	358,776	808,015	1,166,791	434,851	938,500	1,373,351
Net assets, end of year	\$ 491,208	\$ 1,141,881	\$ 1,633,089	\$ 358,776	\$ 808,015	\$ 1,166,791

See accompanying notes.

Baylor College of Medicine
Consolidated Statements of Cash Flows

	Year Ended June 30	
	2021	2020
	<i>(In Thousands)</i>	
Operating activities		
Change in net assets	\$ 466,298	\$ (206,560)
Adjustments to reconcile change in net assets to net cash provided by (used in) operating activities:		
Depreciation and loss on disposal of property and equipment and other	57,104	69,782
Loss on extinguishment of debt	10,343	–
Equity in (gains) losses of unconsolidated affiliates, net	(6,703)	26,700
Equipment acquired through grants and contracts	(11,273)	(9,668)
Investment loss	(3,685)	(3,764)
Change in interest rate swap valuation	(20,751)	33,236
Net realized and unrealized (gains) losses on investments	(506,642)	62,649
Decrease in bond premium/discount and original issue costs	(1,396)	(2,459)
Change in pledges receivable	1,742	20,012
Change in accounts receivable	(23,799)	(17,558)
Gifts and pledges with donor restrictions	(9,986)	(3,732)
Change in other assets	(4,298)	540
Change in assets held on behalf of others	10,999	(2,588)
Change in accounts payable and other liabilities	53,688	19,747
Change in deferred revenue	24,404	(37,377)
Net cash provided by (used in) operating activities	<u>36,045</u>	<u>(51,040)</u>
Investing activities		
Purchases of investments	(140,807)	(115,045)
Proceeds from sales of investments	205,032	120,507
Return of capital – Baylor St. Luke’s Medical Center	5,625	11,250
Purchases of property and equipment	(30,794)	(48,397)
Investment income	3,685	3,764
Issuances of notes receivable	(3,248)	(5,711)
Repayment of notes receivable	3,725	3,110
Net cash provided by (used in) investing activities	<u>43,218</u>	<u>(30,522)</u>
Financing activities		
Proceeds from line of credit	–	19,000
Repayment for line of credit	(45,000)	–
Repayment of bonds payable	(7,275)	(10,095)
Amount placed in escrow to legally defease bonds	(206,011)	–
Issuance costs on bonds	(2,009)	–
Proceeds from issuance of bonds and notes payable, net of issuance costs	208,020	–
Gifts and pledges with donor restrictions	9,986	3,732
Cash flows from financing leases	(464)	(464)
Net cash (used in) provided by financing activities	<u>(42,753)</u>	<u>12,173</u>
Net change in cash, cash equivalents, restricted cash, and restricted cash equivalents	36,510	(69,389)
Cash, cash equivalents, restricted cash, and restricted cash equivalents at beginning of year	<u>80,792</u>	<u>150,181</u>
Cash, cash equivalents, restricted cash, and restricted cash equivalents at end of year	<u>\$ 117,302</u>	<u>\$ 80,792</u>

Baylor College of Medicine

Consolidated Statements of Cash Flows (continued)

	Year Ended June 30	
	2021	2020
	<i>(In Thousands)</i>	
Reconciliation of cash, cash equivalents, restricted cash, and restricted cash equivalents		
Cash and cash equivalents	\$ 44,277	\$ 29,241
Restricted cash and cash equivalents included in investments	73,025	50,571
Restricted cash and cash equivalents included in interest rate swap collateral	-	980
Cash, cash equivalents, restricted cash, and restricted cash equivalents	\$ 117,302	\$ 80,792
Supplemental disclosures		
Net interest paid on bonds	\$ 22,276	\$ 29,251
Noncash investing and financing activities:		
Increase (decrease) in security lending collateral	\$ 91,010	\$ (17,283)
Increase (decrease) in payable under security lending agreement	91,010	(17,283)

See accompanying notes.

Baylor College of Medicine

Notes to Consolidated Financial Statements

June 30, 2021

1. Organization

Baylor College of Medicine (the College or Baylor) is one of the leading health science universities and biomedical research institutions in the United States. Founded in 1900, Baylor owns and operates educational, research, and patient care facilities. The College is an institution comprising four separate colleges, including a medical school, a graduate school of biomedical sciences, a health professions school, and a national school of tropical medicine. Baylor trains more than 3,500 medical, graduate, nurse anesthesia, physician assistant, orthotics and prosthetics, and genetics counseling students, as well as residents and postdoctoral fellows, each year. The College ranks among the nation's top biomedical research institutions and the country's top medical schools. Finally, the College provides extensive patient care services through its wholly owned Baylor Medicine Clinic and through faculty physician service agreements primarily with eight independently owned and operated affiliated hospitals, including Baylor St. Luke's Medical Center; see description below.

Baylor's main campus is located in the Texas Medical Center, a 700-acre complex of approximately 50 independent institutions and state instrumentalities in Houston, Texas. The College is the only private medical school in the southwestern United States.

Effective January 1, 2014, St. Luke's Health System Corporation (n/k/a CHI St. Luke's Health), a Texas nonprofit corporation exempt from federal income tax under Section 501(a) of the Internal Revenue Code of 1986, as amended (the Code), as an organization described in Section 501(c)(3) of the Code, conveyed to the College a 35% membership interest in St. Luke's Medical Center (n/k/a CHI St. Luke's Health Baylor College of Medicine Medical Center), a Texas nonprofit corporation exempt from federal income tax under Section 501(a) of the Code, as an organization described in Section 501(c)(3) of the Code. CHI St. Luke's Health retained a 65% membership interest in CHI St. Luke's Health Baylor College of Medicine Medical Center (BSLMC), which owns and operates a quaternary care hospital in the Texas Medical Center; other land and improvements in and near the Texas Medical Center; and ambulatory clinics located in the Texas Medical Center area, Tanglewood, and Pearland. As consideration, the College contributed to BSLMC cash, certain real property, and improvements, including a portion of the real property generally known as the McNair Campus; the hospital/clinic building located on the McNair Campus (except for a portion of the top five floors to be used for the College's clinical operations and a conference center on the first floor); and, effective February 16, 2015, the ambulatory surgery center located in the Lee and Joe Jamail Specialty Care Center. BSLMC sold the O'Quinn Medical Tower in 2016. The College and CHI St. Luke's Health share governance of BSLMC: each member appoints, and has the unilateral ability to remove, six voting board members and one nonvoting board member. Doing business under the name Baylor St. Luke's Medical Center, the hospital serves as the home of most of the College's medical doctors dedicated to caring for private adult inpatients.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

1. Organization (continued)

Effective February 2, 2015, the College formed a joint venture with H.U. Group (HUG, formerly Miraca Holdings, Inc.), a company based in Tokyo, Japan, and traded on the Tokyo Stock Exchange. HUG is dedicated to in vitro diagnostic, clinical laboratory testing, and other health-care-related businesses through its subsidiaries, such as Fujirebio Inc., one of the major Japanese domestic in vitro diagnostic reagent manufacturers, and SRL, Inc., the largest clinical laboratory testing company in Japan. Under the agreement, the College contributed its clinical genetics diagnostic laboratories business (including leases, equipment, receivables, other contracts, and certain employees) into a subsidiary company and conveyed a 60% membership interest in the subsidiary to a HUG affiliate for \$135.9 million in cash. The College retained a 40% membership interest. The College and the HUG affiliate share governance of the joint venture, called Baylor Miraca Genetics Laboratories, LLC (Baylor Genetics), a Texas limited liability company, and the College retained certain approval rights over aspects of Baylor Genetics that relate to the College's mission.

2. Summary of Significant Accounting Policies

Basis of Accounting and Reporting

The accompanying consolidated financial statements of Baylor have been prepared in conformity with accounting principles generally accepted in the United States of America (U.S. GAAP). The accompanying consolidated financial statements include the accounts of all entities in which Baylor has a significant financial interest and over which Baylor has control. All intercompany accounts and transactions have been eliminated upon consolidation. Baylor Medical Foundation (the Foundation) is consolidated in the College's consolidated financial statements. The Foundation is a Texas nonprofit corporation organized exclusively to aid, support, and maintain the College through contributions received from third-party donors. Baylor's membership interests in BSLMC and Baylor Genetics are included in the College's consolidated financial statements as equity method investments.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

Based on the existence or absence of donor-imposed restrictions, Baylor classifies resources into two categories: net assets without donor restrictions and net assets with donor restrictions.

Net assets without donor restrictions are free of donor-imposed restrictions. All revenues, gains, and losses that are not restricted by donors are included in this classification. All expenditures are reported in the without donor restrictions category since the use of restricted gifts and pledges in accordance with donors' stipulations results in the release of the restriction. Net assets without donor restrictions may be designated for specific purposes by the College's Board of Trustees.

Net assets with donor restrictions are subject to donor-imposed restrictions. Some donor-imposed restrictions expire with the passage of time or can be satisfied by action of the College. Other donor-imposed restrictions are perpetual in nature. These net assets may include unconditional pledges, interests in trusts held by others, accumulated appreciation on donor-restricted endowments that have not yet been appropriated by the Board of Trustees for distribution, and donor-restricted endowments (at historical value). Generally, the donors of these assets permit the College to use a portion of the income earned on related investments for specific purposes.

Expirations of donor-imposed restrictions on net assets (i.e., the passage of time along with the annual board approval of the endowment spending rate and/or fulfilling donor-imposed stipulations) are reported as net assets released from restrictions between the applicable classes of net assets on the consolidated statement of activities. Net assets with donor-imposed restrictions related to the purchase or construction of property and equipment are released when the property or equipment is placed in service, unless donor stipulations limit the use of the assets for a period of time or for a particular purpose.

Net assets with donor restrictions as of June 30, 2021 and 2020, are principally restricted for research and education.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, and expenses during the reporting period, as well as the disclosure of contingent assets and liabilities. Actual results ultimately could differ from management's estimates and assumptions.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

Cash Equivalents

Cash and cash equivalents are liquid assets with minimal interest rate risk and original maturities of three months or less when purchased. Such assets, reported at fair value, primarily consist of depository account balances, money market funds, and short-term U.S. treasury securities

Restricted cash and cash equivalents represent amounts set aside for long-term investments or posted as collateral as required by interest rate swap agreements. These amounts are included in investments, including securities loaned and interest rate swap liability, net on the consolidated balance sheets.

Patient Receivables

Patient receivables are reported at the amount that reflects the consideration to which the College expects to be entitled in exchange for providing physician health care services. Patient receivables include discounts for contractual, implicit price concession and charity adjustments and are recorded on an accrual basis at net realizable value on the consolidated balance sheets. The estimates of implicit price concessions for patient receivables are based primarily on the aging of the receivables and the College's historical collection and write-off experience (see Note 4).

Affiliate Receivables

Affiliate receivables consist of amounts owed by various affiliated hospitals to which the College provides medical, professional, and supervisory staff to deliver patient care, teaching, and staff leadership services. These receivables are recorded on an accrual basis at net realizable value on the consolidated balance sheets.

Grants and Contracts, and Other Receivable

Grants and contracts, and other receivable primarily represent unreimbursed grant and contract expenditures from the federal government, principally the National Institutes of Health, and other nonfederal sources for payment for research provided by the College. These amounts are recorded on an accrual basis at net realizable value on the consolidated balance sheets.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

Pledges Receivable

Unconditional promises to give that are expected to be collected within one year are recorded at net realizable value. Unconditional promises to give that are expected to be collected in future years are recorded at fair value, which is measured as the present value of their future cash flows. The discounts on those amounts are computed using risk-adjusted interest rates applicable to the years in which the promises are received. Amortization of the discounts is included in gifts and pledges revenue.

An allowance is made for uncollectible pledges receivable based upon the College's analysis of past collection experience and other judgmental factors.

Investments

The College's investments in marketable equity and fixed-income securities are recorded at fair value. Non-marketable securities are securities for which no public market exists; substantially all of these securities are accounted for at fair value using the practical expedient of net asset value per share or the equivalent. These non-marketable securities include investments in private equity limited liability corporations or partnerships. Other investments are stated at cost or fair value at the date of the acquisition or donation.

Realized gains and losses arising from the sale or other disposition of investments have been accounted for as changes in net assets without donor restrictions unless restrictions have been imposed by the donor. Certain investments are pooled with each fund subscribing to or disposing of units on the basis of the market value per unit, which is computed monthly. Realized gains and losses arising from the sale of securities are determined on an average cost basis.

The College's intent is to maintain a long-term investment portfolio to support research, education, and other activities. Accordingly, the total investment return is reported on the consolidated statements of activities in two categories. The investment return allocated to operating activities is determined by a formula, which involves allocating 5% of a trailing 28-quarter average market value of the endowment assets. Management believes this return is approximately equal to the real return the College expects to earn on its investments over the long term. The unallocated investment return, included in nonoperating activities on the consolidated statements of activities, represents the difference between the total investment return and the amount allocated to operating activities, net of investment costs.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

Securities Lending

The College participates in securities lending transactions whereby a portion of its investments are loaned, through its agent, under respective borrowing agreements to various parties. In return, the parties provide collateral for the securities loaned, usually on a short-term basis. The collateral consists of eligible securities that meet credit quality criteria and diversification limits in accordance with noncash collateral guidelines selected by the College. The College's claim on the collateral is limited to the market value of the loaned securities. Market values of the securities on loan and the collateral are monitored each business day by the agent to ensure the collateral is maintained at levels of at least 100% of the fair value of the securities on loan. Upon termination of a borrowing agreement or as deemed necessary by the agent, the agent is to deliver identical collateral or a portion of it to satisfy the College's obligations with the borrower. The collateral and the obligation of the College to return the collateral is reported as an asset and liability, respectively, on the consolidated balance sheets at the fair value of the underlying securities. The fees received for these transactions are recorded as investment income.

Property and Equipment

Purchased property, plant, and equipment are recorded at cost, including, where appropriate, capitalized interest and software costs. Donated assets are recorded at fair value at the date of donation. Repairs and maintenance costs are expensed as incurred. Depreciation is calculated using the straight-line method to allocate the cost of various classes of assets over their estimated useful lives. Property, plant, and equipment are removed from the accounting records at the time of disposal.

Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment charge is recognized when the fair value of the asset or group of assets is less than the carrying value.

Deferred Revenue

Deferred revenue consists of amounts received from grant and contract sponsors, affiliated hospitals, and others for which the College has not yet fulfilled its obligations. These amounts will be recognized in future periods to support the College's medical, education, and research missions once the obligations have been satisfied.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

Assets Held on Behalf of Others

The College holds assets received from others and agrees to use those assets on behalf of or transfer the assets, return on investment of the assets, or both to a specified beneficiary. For the years ended June 30, 2021 and 2020, pooled investments in the amount of \$42.1 million and \$31.1 million, respectively, were held on behalf of the state of Texas (see Note 6). The College also held funds associated with a cooperative agreement with the federal government in the amount of \$11.0 million for the years ended June 30, 2021 and 2020. These funds are appropriated for the use of a federal government facility.

Fair Value Measurements

Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 820, *Fair Value Measurement*, defines fair value, requires expanded disclosures about fair value measurements, and establishes a three-level hierarchy for fair value measurements based on the observable inputs to the valuation of an asset or a liability at the measurement date. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability (exit price) in an orderly transaction between market participants at the measurement date. ASC 820 prioritizes the inputs to the valuation techniques used to measure fair value by giving the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements).

Furthermore, ASC 820 applies to certain investment funds that do not have readily determinable fair values, including private investments, hedge funds, real estate, and other funds. ASC 820 allows for the estimation of the fair value of investments in investment companies for which the investment does not have a readily determinable fair value using net asset value per share or its equivalent. See Note 12 for further discussion of fair value measurement.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

Debt Portfolio Financial Instruments

Long-term debt is reported at carrying value. The College employs derivatives in the form of fixed payor swaps, primarily interest rate exchange agreements, to help manage interest rate risks associated with variable rate debt. Derivative financial instruments are reported at fair value with any resulting gain or loss recognized as a nonoperating item on the consolidated statements of activities. Periodic net cash settlement amounts with counterparties are accounted for as adjustments to interest expense on the related debt.

Parties to interest rate exchange agreements are subject to risk for changes in interest rates, as well as risk of credit loss in the event of nonperformance by the counterparty. Baylor deals only with high-quality counterparties that meet rating criteria for financial stability and creditworthiness. Additionally, certain agreements require the posting of collateral when amounts subject to credit risk under the contracts exceed specified levels. Collateral levels are tied to the College's credit rating. The College records its interest rate swap liability net of collateral posted.

Operating Results

Operating results are broadly defined as changes in net assets without donor restrictions from operating activities and are reported as operating revenues in excess (deficit) of expenses on the consolidated statements of activities. Net assets without donor restrictions are also affected by nonoperating activities, which include gains on formation of joint ventures; equity in earnings or losses that are not integral to operations; investment income/loss and other, net of distributions; change in the fair value of interest rate swap agreements; gifts and pledges for plant facilities; and certain other nonrecurring items.

Charity Care

The College is committed to providing assistance to financially indigent patients in the community who require care and services at reduced or no cost, as determined by its affiliated hospitals. Records are maintained to identify and monitor the level of charity care the College provides. These records include the amount of charges forgone and estimated costs for services and supplies furnished under its charity care policy. Costs incurred are estimated based on a Medicare cost factor applied to total gross charges for indigent patients after reducing costs for any payments received. The level of charity care provided, based on estimated costs, during fiscal years 2021 and 2020 was \$47.1 million and \$62.3 million, respectively.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

Endowment Investments and Income Distribution

The College's investments are managed to achieve the maximum long-term return. Operating investment income distribution and other consists of amounts distributed from the College's endowment funds and from income on operating investments. The amount distributed from the endowment funds to support current operations is determined by the Board of Trustees and is based on a 5% distribution rate applied to a trailing 28-quarter average market value of the endowment portfolio. The Board of Trustees may, in its discretion, designate additional funds to be used for operating purposes. The primary objective of the 5% endowment distribution methodology is to reduce the impact of capital market fluctuations on operational programs. Nonoperating investment income (loss) consists of dividends, interest, and realized and unrealized gains and losses on endowed investments, net of distribution to operations and investment expenses.

Leases

The College recognizes right-of-use (ROU) assets and related lease liabilities in accordance with Accounting Standards Update No. (ASU) 2016-02, *Leases (Topic 842)*.

The College leases various equipment and facilities, including office space. Operating and financing leases with an initial term greater than 12 months are recognized as ROU assets and lease liabilities on the consolidated balance sheets. Financing ROU assets and liabilities are reported as part of property and equipment, net and accounts payable and other liabilities, respectively. ROU assets and related liabilities are recognized on the commencement date on the consolidated balance sheets based on future lease payments, and discounted based on the applicable risk-free interest rate, as permitted under the standard for nonpublic business entities.

Lease payments under certain agreements may escalate over the lease term either by a fixed percentage or a fixed dollar amount. Certain leases may provide for variable lease payments in the form of payments based on index-based (e.g., the U.S. Consumer Price Index) adjustments to lease payments. Baylor's lease terms may include options to extend or terminate the lease. Such options are included in the measurement of the ROU asset and liability, provided the existence of reasonable assurance that the College will exercise the option. The College has no leases that contain residual value guarantees provided by the College as a lessee.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

Income Taxes

The College is a tax-exempt organization as described in Section 501(c)(3) of the Code and is generally exempt from federal income taxes on related income pursuant to Section 501(a) of the Code. Baylor is, however, subject to federal and state income tax on unrelated business income and files unrelated business income tax and other information returns as required by government authorities. Management annually reviews its tax positions and has determined that there are no material uncertain tax positions that require recognition on the accompanying consolidated balance sheets as of June 30, 2021 or 2020.

The Tax Cuts and Jobs Act (the TCJA) was enacted on December 22, 2017. For tax-exempt entities, the TCJA requires organizations to pay excise tax on compensation and net investment income after meeting certain thresholds and record income or losses from unrelated business activities on an activity-by-activity basis, among other provisions. As of and for the year ended June 30, 2021, the College has followed regulations and made reasonable estimates of the provision for income taxes; the compensation excise tax; and the effects, if any, on existing deferred tax balances based on accounting guidance included in ASC 740, *Income Taxes*.

COVID-19

In March 2020, the World Health Organization designated COVID-19 as a global pandemic. Clinical patient volumes, research activities, and related revenue of these services were most significantly impacted beginning in mid-March 2020 as various policies were implemented by federal, state, and local governments in response to the COVID-19 pandemic, including stay-at-home orders, business closures, social distancing, and suspension of elective and nonemergent procedures. The College's Education and Public Services missions were less impacted financially from the pandemic. During this time, the College experienced supply chain disruptions, including significant price increases in medical supplies, particularly personal protective equipment. The pandemic also created significant volatility in the U.S. and global financial markets, which impacted the College's investment portfolio.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

In response to the pandemic, federal and state governments passed legislation and took other administrative actions to provide assistance to organizations impacted by the pandemic. Sources of relief included the Coronavirus Aid, Relief, and Economic Security Act (the CARES Act), which was enacted on March 27, 2020. During fiscal periods 2020 and 2021, the College received a total of \$26.6 million of provider relief funds under the CARES Act. The College has recognized these funds within other revenue in the amounts of \$11.0 million and \$3.4 million for the years ended June 30, 2021 and 2020, respectively, and expects to return \$1.1 million within the 2022 fiscal year. The U.S. Department of Health and Human Services (HHS) expects providers will only use the distributed funds for health-care-related expenses or lost revenue attributable to COVID-19 that are not reimbursed or obligated to be reimbursed from other sources. HHS's interpretation of the underlying terms and conditions of such payments, including auditing and reporting requirements, has evolved since the original requirements were released. Additional guidance or new and amended interpretations of existing guidance on the terms and conditions of such payments may result in changes in the College's estimates, and any such changes may result in the College's inability to recognize additional payments or may result in the derecognition of amounts recognized. The remaining payments of \$12.2 million received by the College are recorded in accounts payable and other liabilities and represent the estimated amount that could potentially be adjusted should guidance and reporting requirements change.

The College continues to evaluate the recognition of these funds as new guidance and reporting requirements become available during fiscal year 2022.

The CARES Act also established the Higher Education Emergency Relief Fund (HEERF I). Subsequent to HEERF I, the Coronavirus Response and Relief Supplemental Appropriations Act and the American Rescue Plan established HEERF II and HEERF III (collectively, HEERF) to provide additional funding to institutions and students. The College was made available a total of \$1.9 million under HEERF to distribute emergency financial aid grants to students and to cover institutional costs associated with the disruption of campus operations due to COVID-19. Of these funds, the College has drawn \$0.8 million during fiscal year 2021. The remaining funds available to the College are expected to be drawn in fiscal period 2022.

The College has applied for reimbursement of qualifying expenses under the Federal Emergency Management Agency Disaster Relief Fund (FEMA). During the 2021 fiscal period, FEMA obligated \$1.5 million to reimburse the College for these expenses. As of June 30, 2021, the obligated funds were pending review and distribution by the Texas Division of Emergency Management. The College has not recognized these funds as of June 30, 2021.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

2. Summary of Significant Accounting Policies (continued)

The College took additional measures to improve its liquidity. Beginning March 2020, the College began deferring the employer's portion of payroll taxes as allowed under CARES Act Section 2302. As of June 30, 2021, the College has deferred and recorded \$34.1 million of these taxes in accounts payable and other liabilities. Fifty percent of the tax deferral is required to be paid by December 31, 2021, and the remainder is to be paid by December 31, 2022.

Section 2301 of the CARES Act allows for the Employee Retention Credit, a refundable tax credit to encourage eligible organizations whose operations were impacted by COVID-19 to keep employees on their payroll. The College is currently evaluating recovery of costs through this credit.

Effective February 1, 2021, the College has extended the supplemental line of credit. See Note 10 for discussion of the College's credit facility.

Subsequent Events

The College evaluated events and transactions occurring subsequent to June 30, 2021 through October 15, 2021, the date the accompanying consolidated financial statements were issued. During this period, there were no subsequent events that required recognition in the accompanying consolidated financial statements, nor were there any additional nonrecognized subsequent events that require disclosure.

Pending Accounting Pronouncements

In September 2020, the FASB issued ASU 2020-07, *Not-for-Profit Entities (Topic 958): Presentation and Disclosures by Not-for-Profit Entities for Contributed Nonfinancial Assets*. ASU 2020-07 requires not-for-profit entities to present contributed nonfinancial assets as a separate line item on the statement of activities, apart from contributions of cash and other financial assets. The ASU is effective for the College starting July 1, 2021, including interim periods within the reporting period, and will be applied on a retroactive basis. The College is currently evaluating the impact this guidance will have on its consolidated financial statements.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

3. Equity Investments in Unconsolidated Affiliates

The College has a 35% membership interest in BSLMC, which operates as a tax-exempt entity described in Section 501(c)(3) of the Code. The College's investment in BSLMC, which is accounted for under the equity method, was \$269.6 million and \$272.1 million at June 30, 2021 and 2020, respectively. The College recorded earnings from its investment in BSLMC of \$3.1 million in fiscal year 2021, and a loss of \$18.5 million in fiscal year 2020. The College received cash distributions from BSLMC totaling \$5.6 million and \$11.3 million in fiscal years 2021 and 2020, respectively. These contractual distributions expired in December 2020. A summary of BSLMC's reported total assets, liabilities, and net assets at June 30 is as follows (in thousands):

	2021	2020
Total assets	\$ 1,060,723	\$ 1,068,927
Total liabilities	\$ 179,743	\$ 191,460
Total net assets	880,980	877,467
Total liabilities and net assets	\$ 1,060,723	\$ 1,068,927

A summary of BSLMC's reported revenues, expenses, and net income (loss) for the years ended June 30 is as follows (in thousands):

	2021	2020
Revenue	\$ 1,062,600	\$ 952,835
Expenses	(1,062,315)	(1,005,239)
Operating income (loss)	285	(52,404)
Nonoperating income	5,674	6,913
Excess (deficit) of revenues over expenses	\$ 5,959	\$ (45,491)

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

3. Equity Investments in Unconsolidated Affiliates (continued)

The College has a 40% membership interest in Baylor Genetics, which operates as a Texas limited liability company. The College's investment in Baylor Genetics, which is accounted for under the equity method, was \$49.9 million and \$46.1 million at June 30, 2021 and 2020, respectively. The College recorded earnings from its investment in Baylor Genetics of \$1.8 million in fiscal year 2021, and a loss of \$8.5 million in fiscal year 2020. A summary of Baylor Genetics' reported total assets, liabilities, and shareholder's equity at June 30 is as follows (in thousands):

	<u>2021</u>	<u>2020</u>
Total assets	\$ 31,026	\$ 22,652
Total liabilities	\$ 48,110	\$ 46,312
Total shareholder's deficit	(17,084)	(23,660)
Total liabilities and shareholder's deficit	\$ 31,026	\$ 22,652

A summary of Baylor Genetics' reported revenues, expenses, and net income (loss) for the years ended June 30 is as follows (in thousands):

	<u>2021</u>	<u>2020</u>
Revenues	\$ 67,348	\$ 29,918
Expenses	(62,853)	(51,006)
Net income (loss)	\$ 4,495	\$ (21,088)

4. Revenue Recognition

ASC 606, Revenue from Contracts with Customers

Revenue is recognized when control of the promised services is transferred to the customers (students, patients, affiliated hospitals, and governmental entities) in an amount that reflects the consideration the College is entitled to receive in exchange for those services.

The timing of revenue recognition, billings, and cash collections results in accounts receivable and deferred revenue on the consolidated balance sheets. Receivables are recognized only to the extent that it is probable that the College will collect substantially all of the consideration to which the College is entitled in exchange for the services that will be transferred to the customer.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

4. Revenue Recognition (continued)

Tuition and Fees, Net

The performance obligation for tuition and fees, net relates to the training or educating of undergraduate medical, research graduate, and health profession students. Revenue is recognized ratably as services are rendered during the academic semester using the input method based on time elapsed over the academic semester.

The transaction price is the price of tuition net of scholarships, applicable discounts, and refunds.

The College's academic year is consistent with its fiscal year in which students are billed at the beginning of each semester within the fiscal period and payment is due before the semester ends, also within the fiscal period. The College does not receive advance payments from students prior to the start of the fiscal period. No accounts receivable or deferred liabilities related to tuition and fees were recorded within the accompanying consolidated balance sheets as of June 30, 2021 or 2020.

Medical Services, Net

Medical services, net consist of physician health care services in health care facilities, which include inpatient, outpatient, and ambulatory care facilities; physician practices; and other sites. Performance obligations include individual medical services provided to patients in both an inpatient and outpatient setting. Inpatient services are satisfied over time from patient admission to the point when services are no longer required, which is generally at the time of discharge. The inpatient medical services are recognized utilizing the input method of measuring progress, which is based on actual charges incurred. Outpatient services are satisfied at a point in time and revenue is recognized when control of services is transferred. The College believes this method provides a fair depiction of the transfer of services over the term of performance obligations based on the inputs needed to satisfy the obligations. These services are considered to be a single performance obligation.

Because all of its performance obligations relate to contracts with a duration of less than one year, the College has elected to apply the optional exemption provided in Topic 606 and, therefore, is not required to disclose the aggregate amount of transaction price allocated to medical services performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

4. Revenue Recognition (continued)

period. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.

The College uses a portfolio approach to account for categories of patient contracts as a collective group rather than recognizing revenue on an individual contract basis. The portfolios consist of major payor classes. Based on the historical collection trends and other analyses, the College believes that revenue recognized by utilizing the portfolio approach approximates the revenue that would have been recognized if an individual contract approach were used.

The College determines the transaction price of medical services revenue, which involves significant estimates and judgment, based on standard charges for goods and services provided, reduced by explicit and implicit price concessions, including contractual adjustments provided to commercial insurance carriers, health care maintenance organizations, and preferred provider organizations; discounts provided to uninsured and underinsured patients in accordance with policy; and/or implicit price concessions based on the historical collection experience of patient accounts. The majority of what historically was classified as provision for doubtful accounts is now treated as an implicit price concession factored into net medical service revenues.

In addition, the College determines the transaction price associated with services provided to patients who have third-party payor coverage with Medicare and Medicaid based on reimbursement terms per contractual agreements, discount policies, and historical experience.

Laws and regulations governing Medicare and Medicaid programs are complex and subject to interpretation. The College believes that it is in compliance with all applicable laws and regulations and is not aware of any pending or threatened investigations involving allegations of potential wrongdoing. While no such regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as significant regulatory action, including fines, penalties, and exclusion from the Medicare and Medicaid programs. Changes in the Medicare and Medicaid programs could have a material adverse or positive impact on prospective medical services revenues.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

4. Revenue Recognition (continued)

Management has determined that the nature, amount, timing, and uncertainty of revenue and cash flows are affected by the payors. The composition of medical service revenue by payor was as follows (in thousands):

	2021	2020
Managed care	\$ 89,988	\$ 91,067
Medicare	71,425	66,704
Medicaid	52,744	52,193
Self-pay	11,038	7,359
Other	81,440	76,431
	\$ 306,635	\$ 293,754

The composition of patient receivables (net of contractual allowance and implicit price concession) by payor at June 30 was as follows:

	Patient Receivables	
	2021	2020
Managed care	69.5%	66.1%
Medicare	14.9	16.8
Medicaid	12.2	12.6
Self-pay	1.4	2.4
Other	2.0	2.1
	100.0%	100.0%

Affiliated Hospital Contracts

The College has affiliation agreements with hospitals, including, but not limited to, Texas Children's, Harris Health (formerly Harris County Hospital District), Baylor St. Luke's Medical Center, Michael E. DeBakey Veterans Affairs Medical Center, The Methodist Hospital, The Menninger Clinic, MD Anderson Cancer Center, Children's Hospital of San Antonio, and The Institute for Rehabilitation and Research. Under the terms of these agreements, the College conducts administrative, research, and educational activities on behalf of these hospitals.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

4. Revenue Recognition (continued)

The College provides residents to the affiliated institutions; the residents in turn, provide patient care services as part of their medical training. The College satisfies this performance obligation over time as the hospitals receive the benefit of professional services. Affiliated hospital contract revenue is recognized as time elapses for actual personnel and operating costs incurred less collections that are received by the College from patient payors.

Amounts are billed periodically in accordance with agreed-upon contractual terms. The timing of revenue recognition, billings, and cash collections results in billed and unbilled receivables and customer advances and deposits on the consolidated balance sheet. These assets and liabilities are reported on the consolidated balance sheet on a contract-by-contract basis at the end of each reporting period. Affiliate receivables in the amount of \$111.5 million and \$112.5 million were recorded as of June 30, 2021 and 2020, respectively. Affiliate deferred revenue in the amount of \$13.6 million and \$8.8 million is included on the accompanying consolidated balance sheets as of June 30, 2021 and 2020, respectively.

Following were the affiliates that accounted for greater than 10% of total affiliated contract revenue for the years ended June 30:

	<u>2021</u>	<u>2020</u>
BSLMC	18.9%	17.6%
Harris Health	18.2	16.6
Texas Children's	49.7	51.1

Following were the affiliates that accounted for greater than 10% of total affiliated contract receivables as of June 30:

	<u>2021</u>	<u>2020</u>
BSLMC	27.8%	31.8%
Texas Children's	52.3	46.6

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

4. Revenue Recognition (continued)

Other

Other revenue primarily consists of several other exchange contracts, including academic program fees from the College's affiliates, royalties on certain licenses of intellectual property and the Baylor College of Medicine brand, and various other types of income. Depending on the program, revenue is recognized at a point in time or over time as obligations are met.

The College recognized \$9.6 million and \$51.1 million of royalty income in consideration for an exclusive license agreement of Baylor intellectual property during fiscal years 2021 and 2020, respectively. The College recognized CARES Act funding of \$11.0 million and \$3.4 million during fiscal years 2021 and 2020, respectively (see Note 2).

ASC 958-605, Not-for-Profit Entities – Revenue Recognition

State appropriations – The College received funding in the form of appropriations from the State of Texas Higher Education Coordinating Board (the Coordinating Board) for the purpose of training or educating Texas resident undergraduate medical students and graduate medical residents in the amount of \$46.4 million and \$26.1 million in 2021 and 2020, respectively. The College expended \$228.9 million and \$231.0 million for fiscal years 2021 and 2020, respectively, to train and educate undergraduate medical students and graduate medical residents. Expenditures used to satisfy these appropriations are reflected on the schedule of functional expenses (see Note 13) as instruction expenditures and certain amounts related to the instruction of graduate medical residents that are included in affiliated hospital programs expenditures.

The Coordinating Board has approved the transfer of the College's state funding to the Texas Health and Human Services Commission (HHSC) for state fiscal years 2021 and 2020. The purpose of this intergovernmental transfer is to allow the use of the College's state funding to draw down federal dollars under the Section 1115 Medicaid Waiver Program (1115 Waiver).

Because this is a hospital-based program, the College has signed agreements to collaborate with Texas Children's, Houston Methodist Hospital, and CHI St. Luke's Health, pursuant to which these affiliates will transfer to the College the amounts the College normally would receive from the Coordinating Board. All agreements include a provision that the original appropriation will be returned to the College if the federal match anticipated under the 1115 Waiver does not occur. Amounts under these arrangements are recognized as affiliated hospital contracts, of which the College recognized \$2.8 million and \$20.4 million during the years ended June 30, 2021 and 2020, respectively.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

4. Revenue Recognition (continued)

Following the end of the Coordinating Board's involvement in the 1115 Waiver with HHSC, effective August 31, 2020, the Legislature's appropriation has been sent directly to the College in support of undergraduate medical education. These amounts are included in state appropriations for the year ended June 30, 2021.

Government and private grants and contracts – Government and private grants and contracts represent revenue from grants and contracts with federal, state, and local governments; private foundations; and corporate sponsors primarily for research and education activities conducted by the College. Direct recoveries are recognized when allowable direct expenditures for salaries and supplies are incurred under the terms of each sponsor's agreement. Indirect recoveries represent reimbursement of the costs of facilities and administrative (F&A) overhead associated with government and private grants and contracts. Indirect recoveries are recognized as revenue as the corresponding allowable direct grant and contract expenses are incurred under the terms of each sponsor's agreement. Baylor's federal F&A costs recovery rate for on-campus research was 60.0% in both fiscal years 2021 and 2020. Baylor's federal F&A costs recovery rate for off-campus research was 26.0% in both fiscal years 2021 and 2020.

Gifts and pledges – As pledges are made to the College, the intent of the donor, circumstances regarding the pledge, and any action taken by the College in response to the pledge are considered in determining whether the pledge is an unconditional promise to give or a conditional promise. Unconditional promises to give (pledges) are recognized as revenue without donor restrictions when the donor's commitment is received. Gifts and pledges with donor-imposed restrictions are recorded as revenue without donor restrictions if those restrictions are met in the same reporting period. Otherwise, gifts and pledges with donor-imposed restrictions are recorded as increases in net assets with donor restrictions.

Conditional promises (primarily bequest intentions) are not recorded until donor conditions are substantially met.

Gifts and pledges recorded as donor-restricted net assets are released from restrictions and recognized as net assets without restrictions after any donor stipulations are met. Gifts and pledges for plant facilities are released from restrictions and recognized as a nonoperating item only after resources are expended for the applicable plant facilities.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

5. Pledges Receivable

Pledges receivable as of June 30 are expected to be realized as follows (in thousands):

	2021	2020
In one year or less	\$ 24,407	\$ 23,857
Between one year and five years	12,015	14,721
More than five years	10,620	11,600
Less present value discount	(4,958)	(6,352)
Total	\$ 42,084	\$ 43,826

Included in pledges receivable at June 30, 2021 and 2020, is \$3.9 million and \$6.5 million, respectively, to support the development of BSLMC. As of June 30, 2021 and 2020, the College had received conditional promises to give and indications of intentions to give of approximately \$32.7 million and \$29.6 million, respectively, in addition to the amounts recorded as pledges receivable. These conditional promises to give will be recognized in the accompanying consolidated financial statements in the periods in which the conditions are substantially met.

6. Investments

Investments (including amounts for self-insurance) held by the College at June 30 are as follows (in thousands):

	2021	2020
Pooled investments:		
Stocks	\$ 488,656	\$ 423,198
Bonds	106,073	97,083
Other short-term investments	73,025	50,571
International equities	481,622	287,343
Private equity securities	521,408	348,384
Total pooled investments	1,670,784	1,206,579
Other stocks	5,279	5,889
Real estate, at cost	2,656	2,656
Assets held in trust and other	10,759	9,482
Total investments	\$ 1,689,478	\$ 1,224,606

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

6. Investments (continued)

In fiscal year 2000, the College received \$25.0 million to establish a fund for investing a portion of receipts paid to the state of Texas under a judgment rendered in the tobacco settlement (the tobacco funds). The College is responsible for the administration of the tobacco funds, which are invested along with the College's pooled investments; however, the College does not have title to the assets. As of June 30, 2021 and 2020, the value of the tobacco funds is included in pooled investments and a corresponding liability has been recorded in assets held on behalf of others to reflect that the College does not currently have an ownership interest.

The earnings of the tobacco funds are required to be remitted to the state of Texas, which, in turn, appropriates the earnings to the College to benefit programs in medical research, health education, and treatment. The distributions in the years ended June 30, 2021 and 2020, of \$3.6 million and \$3.8 million, respectively, are included in state appropriations on the consolidated statements of activities.

The U.S. and international financial markets have experienced significant volatility that has resulted in substantial fluctuations in equity markets in which the College invests. Market volatility can affect the value the College receives for its investments in future periods.

Investment performance for the years ended June 30 is summarized as follows (in thousands):

	2021			
	Operating	Nonoperating	With Donor Restrictions	Total
Distribution of endowment earnings and other	\$ 3,986	\$ —	\$ 6	\$ 3,992
Investment income	—	16,056	709	16,765
Net realized (losses) gains	(199)	128,768	5,058	133,627
Net unrealized gains	—	37,442	309,132	346,574
Total investment return	3,787	182,266	314,905	500,958
Investment return, designated for current operations	58,637	(58,828)	191	—
Investment management fees	(4,241)	(4,658)	—	(8,899)
Total investment return, net of distributions and expenses	<u>\$ 58,183</u>	<u>\$ 118,780</u>	<u>\$ 315,096</u>	<u>\$ 492,059</u>

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

6. Investments (continued)

	2020			
	Operating	Nonoperating	With Donor Restrictions	Total
Distribution of endowment earnings and other	\$ 924	\$ –	\$ 8	\$ 932
Investment income	–	10,922	671	11,593
Net realized gains	4,082	34,493	1,266	39,841
Net unrealized gains (losses)	–	11,208	(112,682)	(101,474)
Total investment return	5,006	56,623	(110,737)	(49,108)
Investment return, designated for current operations	56,550	(56,732)	182	–
Investment management fees	(2,970)	(5,424)	–	(8,394)
Total investment return (loss), net of distributions and expenses	\$ 58,586	\$ (5,533)	\$ (110,555)	\$ (57,502)

7. Endowment Funds

The College's endowment consists of approximately 800 individual funds established for a variety of purposes. Its endowment includes both donor-restricted endowment funds and funds designated by the College to function as endowments. As required by U.S. GAAP, net assets associated with endowment funds, including funds designated by the College to function as endowments, are classified and reported based on the existence or absence of donor-imposed restrictions.

ASC 958-205-45-28, *Not-for-Profit Entities – Presentation of Financial Statements – Other Presentation Matters – Classification of Donor-Restricted Endowment Funds Subject to UPMIFA*, provides guidance on the net asset classification of donor-restricted endowment funds for a not-for-profit organization that is subject to an enacted version of the Uniform Prudent Management of Institutional Funds Act of 2006 (UPMIFA) and improves disclosures about an organization's endowment funds (both donor-restricted and College-designated endowment funds).

Interpretation of relevant law – The College has established policy consistent with UPMIFA as adopted by the state of Texas. The College seeks to preserve the fair value of the original gift as of the gift date of the donor-restricted endowment funds absent explicit donor stipulations to the contrary. Accordingly, the College classified as net assets with donor restrictions (a) the original value of gifts donated to the permanent endowment, (b) the original value of subsequent gifts to the permanent endowment, and (c) accumulations to the permanent endowment made in accordance with the direction of the applicable donor agreement at the time the accumulation is

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

7. Endowment Funds (continued)

added to the fund. The remaining portion of the donor-restricted endowment fund that is not classified as permanent endowment is available for appropriation for expenditure by the College in a manner consistent with the standard of prudence prescribed by UPMIFA.

In accordance with UPMIFA, the College considers the following factors in making a determination to appropriate or accumulate donor-restricted endowment funds:

- (1) The duration and preservation of the fund
- (2) The purposes of the College and the donor-restricted endowment fund
- (3) General economic conditions
- (4) The possible effect of inflation and deflation
- (5) The expected total return from income and the appreciation of investments
- (6) Other resources of the College
- (7) The investment policies of the College

The College's endowment consists of the following net asset types at June 30 (in thousands):

	Without Donor Restrictions	With Donor Restrictions	Total
2021			
Donor-restricted endowment funds	\$ —	\$ 963,638	\$ 963,638
Board-designated endowment funds	687,309	16,715	704,024
Total endowments at June 30, 2021	\$ 687,309	\$ 980,353	\$ 1,667,662

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

7. Endowment Funds (continued)

	Without Donor Restrictions	With Donor Restrictions	Total
2020			
Donor-restricted endowment funds	\$ –	\$ 645,764	\$ 645,764
Board-designated endowment funds	543,126	12,165	555,291
Total endowments at June 30, 2020	\$ 543,126	\$ 657,929	\$ 1,201,055

Funds with deficiencies – From time to time, the fair value of the assets associated with the individual donor-restricted endowment funds may fall below the level that the donor or UPMIFA requires the College to retain as a fund of perpetual duration. As of June 30, 2021, the College had no deficiencies of this nature in donor-restricted endowment funds. As of June 30, 2020, the College had deficiencies of this nature in 70 donor-restricted endowment funds, which together had an original gift value of \$41.0 million, a fair value of \$38.8 million, and a deficiency of \$2.2 million. These deficiencies result from unfavorable market fluctuations and continued appropriation of certain programs that was deemed prudent by the Board of Trustees. The College maintains policies that permit spending from underwater endowment funds depending on the degree to which the fund is underwater, unless otherwise precluded by donor intent or relevant laws and regulations.

Return objectives and risk parameters – The College recognizes that the goals of endowment management are preserving the purchasing power of the assets and providing stable support for current programs. The primary focus of the College’s endowment investment policy is structuring both the endowment’s investment portfolio and its annual spending in order to balance the needs of current and future generations of scholars, scientists, patients, and teachers. Current annual spending from the endowment plus inflation combines to create a minimum target total return for the portfolio. The College expects its endowment funds, over time, to provide an average rate of return at least equal to the spending policy requirements plus the rate of inflation. Actual rates of return in any given year may vary from this amount.

Strategies employed for achieving objectives – The College employs strategies of investing in equity assets and some illiquid assets, broadly diversifying, and investing in assets that are out of favor. The College believes that these strategies will help achieve the total return target over the long term.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

7. Endowment Funds (continued)

Spending policy and how the investment objectives relate to spending policy – The College’s board-approved endowment earnings distribution policy, as permitted by UPMIFA, is based on a 5% distribution applied to a trailing 28-quarter average market value of the endowment assets for both fiscal years. In establishing this spending policy, the College considered the long-term expected return on its endowment assets and expects the current spending policy to preserve the real purchasing power of the endowment assets, while helping to maintain intergenerational value of the assets, as well as to provide additional real growth through new gifts and pledges and investment return.

The following endowment-related activities occurred during the years ended June 30 (in thousands):

	Without Donor Restrictions	With Donor Restrictions	Total
Endowment net assets at June 30, 2020	\$ 543,126	\$ 657,929	\$ 1,201,055
Investment income, net of expense	15,471	777	16,248
Gifts and pledges	36	8,729	8,765
Realized and unrealized gains, net	176,861	312,918	489,779
Appropriation of endowment assets for expenditure	(58,828)	–	(58,828)
Other changes:			
Transfer to/from board-designated endowments within net assets without donor restrictions	10,643	–	10,643
Endowment net assets at June 30, 2021	<u>\$ 687,309</u>	<u>\$ 980,353</u>	<u>\$ 1,667,662</u>

	Without Donor Restrictions	With Donor Restrictions	Total
Endowment net assets at June 30, 2019	\$ 546,346	\$ 764,471	\$ 1,310,817
Investment income, net of expense	9,625	734	10,359
Gifts and pledges	7	5,604	5,611
Realized and unrealized gains (losses), net	43,880	(112,820)	(68,940)
Appropriation of endowment assets for expenditure	(56,732)	–	(56,732)
Other changes:			
Transfer to/from board-designated endowments within net assets without donor restrictions	–	(60)	(60)
Endowment net assets at June 30, 2020	<u>\$ 543,126</u>	<u>\$ 657,929</u>	<u>\$ 1,201,055</u>

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

8. Financial Assets and Liquidity Resources

The table below represents financial assets and liquidity resources available for general expenditures within one year. The College defines general expenditures as the normal expenditures related to operations, excluding capital expenditures (in thousands).

	2021	2020
Financial assets:		
Cash and cash equivalents	\$ 44,277	\$ 29,241
Accounts receivable	259,163	235,364
Pledges receivable	42,084	43,826
Notes receivable	17,389	17,866
Investments, including securities loaned of \$98,756 and \$17,089 for 2021 and 2020, respectively	1,689,478	1,224,606
Security lending collateral	108,711	17,701
Total financial assets	2,161,102	1,568,604
Liquidity resource:		
Unused bank line of credit	250,000	205,000
Less those unavailable for general expenditures within one year due to:		
Contractual or donor-imposed restrictions	(980,353)	(657,929)
Investments with liquidity restrictions	(3,468)	(3,689)
Investments held in trust	(10,759)	(9,482)
Pledges receivable	(17,677)	(19,969)
Notes receivable	(17,389)	(17,866)
Assets held on behalf of others	(53,105)	(42,106)
Security lending collateral	(108,711)	(17,701)
Financial assets not available for use within one year	(1,191,462)	(768,742)
Financial assets and liquidity resources available for general expenditures within one year	\$ 1,219,640	\$ 1,004,862

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

8. Financial Assets and Liquidity Resources (continued)

The College's endowment funds consist of donor-restricted endowments and funds designated by the board as endowment. Income from endowments is restricted for specific purposes. The College has a spending policy and \$59.3 million of appropriation from the endowments will be available in the next 12 months. As part of a liquidity management plan, the College has a policy to structure its financial assets to be available as its general expenditures, liabilities, and other obligations come due. Cash in excess of daily requirements is invested in short-term investments. In the event of an unanticipated liquidity need, the College has a 4-year, \$150.0 million line of credit available for working capital purposes, and a supplemental 364-day, \$100.0 million line of credit related to the COVID-19 pandemic (see Note 10).

9. Property and Equipment

Property and equipment consist of the following at June 30 (in thousands):

	Useful Life (Years)	2021	2020
Land	–	\$ 5,269	\$ 5,269
Buildings	17–50	729,609	706,426
Land improvements	15–20	17,017	16,483
Leasehold improvements	5–15	98,619	96,587
Furniture and equipment	5–10	350,425	337,308
Computer software	3–5	110,211	109,108
		1,311,150	1,271,181
Less accumulated depreciation		(958,057)	(914,675)
		353,093	356,506
Construction-in-progress		35,384	46,056
Leased right-of-use assets – financing		1,250	1,430
		\$ 389,727	\$ 403,992

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

9. Property and Equipment (continued)

In accordance with ASC 360, *Property, Plant, and Equipment*, when events or changes in circumstances indicate the carrying amount of property and equipment, and intangible or other long-lived assets, related to specifically acquired assets may not be recoverable, an evaluation of the recoverability of currently recorded costs is performed. When an evaluation is performed, the estimated value of undiscounted future net cash flows associated with the asset is compared with the asset's carrying value to determine whether a write-down to fair value is required. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the assets exceeds the fair value of the assets. No impairments were recognized for the years ended June 30, 2021 or 2020.

10. Bonds and Notes Payable

A summary of bonds and notes payable at June 30 is as follows (in thousands):

	2021		2020
2012A Bond Series			
In September 2012, the Harris County Cultural Education Facilities Finance Corp. issued for the College \$202.88 million of tax-exempt fixed rate bonds. Interest rates range from 3.00% to 5.00%, payable semiannually. See 2020 Bond Series note below on advance refunding of this series.	\$	–	\$ 184,950
2012 Bond Series			
In September 2012, the College issued \$109.1 million of taxable fixed rate bonds. The interest rate is 5.26%, payable semiannually. Mandatory annual redemption before maturity is required between November 15, 2038 and 2045, with final maturity on November 15, 2046.		109,121	109,121
2016 Bond Series			
In May 2016, the Harris County Cultural Education Facilities Finance Corp. issued for the College \$142.66 million of tax-exempt fixed rate bonds with multiple maturities. The interest rates range from 3.00% to 5.00%, payable semiannually. Beginning in November 2018, principal installments are due annually with final maturity at November 15, 2032. A majority of the outstanding bonds are callable beginning in May 2026.		121,765	129,040

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

10. Bonds and Notes Payable (continued)

	2021	2020
2019A Bond Series		
In May 2019, the College retired \$75 million of tax-exempt floating rate notes with the Harris County Cultural Education Facilities Finance Corp. The Harris County Cultural Education Facilities Finance Corp. simultaneously issued \$75 million of tax-exempt floating rate notes. The interest rate resets monthly at a spread of 0.65% over the one-month London Interbank Offered Rate (LIBOR). The interest rate at June 30, 2021, was 0.715%. These bonds mature on November 15, 2046, but have an initial mandatory repurchase in July 2024.	\$ 75,000	\$ 75,000
2019B Bond Series		
In May 2019, the College retired a \$75 million direct placement loan with Barclays Bank. The Harris County Cultural Education Facilities Finance Corp. simultaneously issued \$75 million of tax-exempt floating rate notes. The interest rate resets monthly at a spread of 0.65% over the one-month LIBOR. The interest rate at June 30, 2021, was 0.715%. This bond matures on November 15, 2046, but has an initial mandatory repurchase in July 2022.	75,000	75,000
2020 Bond Series		
In November 2020, the Harris County Cultural Education Facilities Finance Corporation issued for the College the Taxable Medical Facilities Mortgage Revenue Refunding Bonds for \$208.02 million. The interest rates, payable semiannually, range from 1.4% to 3.9%. Principal installments are due annually beginning in 2022 and through 2030 with additional maturities due in 2037 and 2046. The proceeds from this issuance were used to advance refund the Bonds Series 2012A.	208,020	—
Total outstanding	588,906	573,111
Less deferred issuance costs	(4,366)	(4,123)
Plus original issue premium – 2012A Bond Series	—	7,779
Plus original issue premium – 2016 Bond Series	8,454	9,928
	\$ 592,994	\$ 586,695

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

10. Bonds and Notes Payable (continued)

As part of the taxable 2020 Bond Series issuance (2020 Bond Series), \$184.95 million of the 2012A Bond Series was legally defeased by establishing an irrevocable escrow account to fund the debt service until the applicable maturity or redemption dates.

The aggregate annual scheduled maturities of long-term debt as of June 30, 2021, for the next five fiscal years and thereafter are as follows (in thousands):

2022	\$	7,545
2023		14,385
2024		14,880
2025		15,410
2026		15,980
Thereafter		<u>520,706</u>
	\$	<u>588,906</u>

In addition, the College must purchase a portion of its debt within these fiscal years unless remarketed, as described above.

Advance refunding tax-exempt debt is subject to arbitrage rules under Code Section 103(c) and related regulations that, in general, prohibit the yield realized from the investment of the proceeds of the new debt from exceeding the yield on the debt itself. Compliance with those rules is necessary for the interest on the debt to be exempt from federal income tax, and the College believes that it is in compliance with those rules.

As of June 30, 2021, all bonds outstanding have been issued under terms of the Second Amended and Restated Master Trust Indenture, dated November 1, 2020, between the Master Trustee and the College. The Master Trustee has a secured interest in all gross receipts and substantially all College land, including all improvements, appurtenances, personal property, and proceeds now or hereafter placed, acquired, or arising from the land.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

10. Bonds and Notes Payable (continued)

Bond Compliance

As of June 30, 2021, the College is in compliance with financial covenants per the Second Amended and Restated Master Trust Indenture dated November 1, 2020.

Revolving Credit Line

The College maintains a \$150.0 million revolving line of credit that is scheduled to expire on June 30, 2024. No funds were outstanding under the line of credit as of June 30, 2021. The College had drawn \$45.0 million for working capital purposes as of June 30, 2020. Effective April 9, 2020, the College secured a supplemental 364-day, \$100.0 million line of credit that provides additional liquidity and flexibility during the COVID-19 pandemic. Effective February 1, 2021, the supplemental line of credit was extended for an additional year through April 8, 2022. As of June 30, 2021, there is no balance outstanding on this supplemental line of credit.

11. Derivative and Other Financial Instruments

The College has derivative financial instruments, as allowed by its Debt and Swap Policies' Guidelines, both of which specifically preclude their use for speculation. The College has three fixed payor swaps outstanding at June 30, 2021 and 2020. During fiscal year 2020, the College novated the front 12 years of its swap transaction with Barclays Bank PLC to PNC Bank, N.A. (PNC Bank) while the remaining years remained with Barclays as a forward starting swap with zero notional amount. As a result of the novation, the fixed rate paid by the College increased from 4.274% to 4.542% and all the posted collateral with Barclays Bank PLC was released. The PNC Bank swap transaction does not have any collateral posting requirements. Also during 2020, the College executed an amendment to its outstanding swap transaction with Bank of America, N.A. increasing the collateral posting threshold from \$20.0 million to \$30.0 million. The fixed rate paid by the College increased from 4.443% to 4.554%. The notional amount reduction for the Bank of America, N.A. swap in fiscal year 2022 will be \$0.5 million. The notional increase in fiscal year 2022 will be \$0.5 million for the PNC Bank swap.

The College has not elected hedge treatment of these swap agreements; as such, the change in the fair value of interest rate swaps is recorded in nonoperating unrealized loss on interest rate swaps on the consolidated statements of activities and as an adjustment to reconcile operating activity on the consolidated statements of cash flows. These long-dated swaps have a predetermined annual notional amortization or accretion that occurs in November each year.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

11. Derivative and Other Financial Instruments (continued)

The following table summarizes the fair value from the College's perspective at June 30, and the income (loss) recorded related to the interest rate swap agreements as of and for the years ended June 30 (dollars in thousands):

Counterparty	Barclays Bank PLC	PNC Bank	Bank of America/ Merrill Lynch	Total
Description	Fixed rate	Fixed rate	Fixed rate	
Effective date	February 2032	February 2020	January 2012	
Termination date	November 2045	February 2032	November 2047	
Notional amount	\$ —	\$ 102,335	\$ 41,465	\$ 143,800
Fixed rate	4.274%	4.542%	4.554%	
Fair value:				
2021	\$ (25,922)	\$ (37,394)	\$ (21,942)	\$ (85,258)
2020	(32,368)	(46,314)	(27,327)	(106,009)
Collateral posted:				
2021	\$ —	\$ —	\$ —	\$ —
2020	—	—	980	980
Gain (loss) recorded:				
2021	\$ 6,446	\$ 8,920	\$ 5,385	\$ 20,751
2020	21,095	(46,314)	(8,017)	(33,236)

12. Fair Value of Assets and Liabilities

The estimated fair values of all significant financial instrument amounts have been determined by the College using available market information and appropriate valuation methodologies. The estimates are not necessarily indicative of the amounts the College could realize in a current market exchange.

The carrying amounts of cash and cash equivalents, accounts receivable, patient accounts receivable, accounts payable, and short-term line of credit approximate fair value because of their short maturity.

The College's bonds payable are reported at carrying value (par) net of unamortized premiums/ discounts.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

12. Fair Value of Assets and Liabilities (continued)

The College records investments, investments loaned under its security lending agreements, the related payable under security lending agreements, and its bond interest rate swap instruments at fair value in accordance with ASC 820.

ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the reporting date. The statement establishes consistency and comparability by providing a fair value hierarchy that prioritizes the inputs to valuation techniques into three broad levels, which are described below.

Level 1 – Inputs are quoted market prices in active markets for identical assets or liabilities (these are observable market inputs) that the College has the ability to access at the reporting date.

Level 2 – Inputs are other than quoted prices included within Level 1 that are either directly or indirectly observable for the asset or liability, including quoted market prices for similar assets in active markets, quoted prices for identical or similar assets in markets in which there are few transactions, inputs other than quoted prices that are observable for the asset, and inputs that are derived from observable market data by correlation or other means.

Level 3 – Inputs are generally unobservable market inputs that typically reflect the entity's estimate of assumptions that market participants would use in pricing the asset or liability (used when little or no market data is available).

ASC 820 requires the use of observable market inputs (quoted market prices) when measuring fair value whenever possible and requires Level 1 quoted prices to be used to measure fair value whenever possible.

ASC 820 provides guidance for estimating the fair value of investments in certain entities that calculate net asset value per share (or its equivalent). As such, the College utilizes net asset value as a practical expedient of fair value and other available information to determine fair value for investments meeting the prescribed requirements.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

12. Fair Value of Assets and Liabilities (continued)

Level 1 investments are able to be liquidated as of the reporting date at published market values. Level 2 and 3 investments may contain restrictions on the ability to liquidate assets at the reporting date. Investments that can be liquidated within 90 days of the reporting date at net asset value or its equivalent are classified as Level 2 investments. Investments classified as Level 3 have significant liquidity restrictions that would prevent redemption within 90 days of the reporting date, if at all. The following tables do not include private equity investments of \$521.4 million and \$365.5 million that are measured at fair value using net asset value as a practical expedient.

Financial assets and liabilities included in the College's consolidated financial statements and measured at fair value on a recurring basis as of June 30 are classified based on the applicable valuation technique level in the following tables (in thousands):

	Total 2021	Quoted Prices in Active Markets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Assets:				
Cash and cash equivalents	\$ 73,025	\$ 73,025	\$ —	\$ —
U.S. equities	497,319	436,644	60,675	—
International equities	481,622	322,855	158,767	—
Fixed income	106,073	26,734	79,339	—
Security lending collateral	108,711	—	108,711	—
	<u>\$ 1,266,750</u>	<u>\$ 859,258</u>	<u>\$ 407,492</u>	<u>\$ —</u>
Liabilities:				
Interest rate swap liability	\$ 85,258	\$ —	\$ 85,258	\$ —
Payable under security lending agreements	108,711	—	108,711	—
Assets held on behalf of others (state tobacco funds)	42,146	42,146	—	—
	<u>\$ 236,115</u>	<u>\$ 42,146</u>	<u>\$ 193,969</u>	<u>\$ —</u>

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

12. Fair Value of Assets and Liabilities (continued)

	Total 2020	Quoted Prices in Active Markets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Assets:				
Cash and cash equivalents	\$ 50,571	\$ 50,571	\$ –	\$ –
U.S. equities	423,198	283,415	139,783	–
International equities	287,343	199,087	88,256	–
Fixed income	97,083	24,379	72,704	–
Security lending collateral	17,701	–	17,701	–
	<u>\$ 875,896</u>	<u>\$ 557,452</u>	<u>\$ 318,444</u>	<u>\$ –</u>
Liabilities:				
Interest rate swap liability	\$ 106,009	\$ –	\$ 106,009	\$ –
Payable under security lending agreements	17,701	–	17,701	–
Assets held on behalf of others (state tobacco funds)	31,145	31,145	–	–
	<u>\$ 154,855</u>	<u>\$ 31,145</u>	<u>\$ 123,710</u>	<u>\$ –</u>

Cash and cash equivalents and U.S. and international equities included in Level 1 are measured using quoted market prices in active markets for the identical equities. U.S. and international equities and fixed-income investments, included in Level 2, are measured using quoted market prices for similar assets and using the net asset value per share.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

12. Fair Value of Assets and Liabilities (continued)

Private equity investments consist of leveraged buy-outs, venture capital, distressed debt, and real assets and real estate investments. Capital is allocated to domestic and international markets in various investment vehicles, primarily limited partnerships, but also includes private real estate investment trusts. Most of the underlying assets in the private equity partnerships are not immediately liquid. All private equity investments are held as long-term investments. Leveraged buy-outs, venture capital, and distressed debt investments are structured as closed-end, commitment-based investment funds where the investor commits a specified amount of capital upon inception of the fund, which is then drawn down over a specified period of the fund's life. These funds generally cannot be withdrawn or redeemed prior to the specified termination date and will only receive distributions upon a disposition of the underlying assets in the portfolio. As a limited partner, the College will not generally have any influence over the amount or timing of capital contributions and distributions. As of June 30, 2021, the remaining specified term of the leveraged buy-outs, venture capital, and distressed debt partnerships ranged from 1 to 12 years. However, a partnership's life may be (and normally is) extended beyond the original specified term by approval of the limited partners. Some of the College's real estate investments are different from the other private equity partnerships, as they are structured as open-ended, commingled investment vehicles. The underlying investments consist of large, diversified portfolios of existing real properties, primarily income-producing assets, such as office buildings, apartments, retail, and industrial properties, located across the United States. Subject to certain restrictions, redemptions of all or part of the College's investments in private equity real estate may be requested each quarter, and such redemptions will be made at the net asset value for the fund. Private equity investment valuation is determined by the private equity general partner using proprietary information that is unobservable to a market participant.

Interest rate swap liability (see Note 11) valuation is determined using market valuation techniques, including discounted cash flow analysis on the expected cash flow of each agreement. This analysis reflects the contractual terms of the agreement, including the period to maturity, and uses observable market-based inputs, including forward interest rate curves. These observable (Level 2) inputs are available to a market participant.

The securities lending collateral (see Note 2) consists of U.S. and non-U.S. obligations, government agency obligations, corporate debt securities, equities from indexes as approved by the securities lending agent's risk committee, and exchange-traded funds. The collateral and associated liability, included in Level 2, are determined using a mark-to-market valuation that is performed each business day.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

13. Functional Expenses

The College's expenses relate principally to providing education, research, and clinical services. The functional expenses for these services are recorded directly or are allocated. Operation and maintenance of plant expense, depreciation expense, and interest expense are allocated to the various functional areas of the College based on the square footage of space occupied by each program and supporting service.

For the years ended June 30, expenses related to providing these services are as follows (in thousands):

	2021						
	Program Activities				Supporting Activities		
	Instruction	Research	Medical Services	Affiliated Hospital Programs	Management and General	Fundraising	Total Expenses
Direct							
Salaries, wages, and benefits	\$ 127,629	\$ 351,523	\$ 297,933	\$ 826,592	\$ 29,875	\$ 4,121	\$ 1,637,673
Services, supplies, and others	14,645	194,871	95,728	37,204	40,332	1,432	384,212
Allocated							
Operations and maintenance of plant	6,200	40,592	1,600	-	-	-	48,392
Depreciation and interest	7,711	63,052	9,807	65	-	-	80,635
Allocated expenses by functional area	\$ 156,185	\$ 650,038	\$ 405,068	\$ 863,861	\$ 70,207	\$ 5,553	\$ 2,150,912
	2020						
	Program Activities				Supporting Activities		
	Instruction	Research	Medical Services	Affiliated Hospital Programs	Management and General	Fundraising	Total Expenses
Direct							
Salaries, wages, and benefits	\$ 131,122	\$ 353,802	\$ 275,250	\$ 795,172	\$ 30,104	\$ 4,448	\$ 1,589,898
Services, supplies, and others	19,603	191,374	83,041	39,761	35,579	3,293	372,651
Allocated							
Operations and maintenance of plant	7,235	40,398	1,364	-	-	-	48,997
Depreciation and interest	9,165	64,942	9,447	63	-	-	83,617
Allocated expenses by functional area	\$ 167,125	\$ 650,516	\$ 369,102	\$ 834,996	\$ 65,683	\$ 7,741	\$ 2,095,163

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

14. Employee Benefits

Retirement Plan

Substantially all faculty and staff participate in the College's defined contribution retirement plan (the Plan). The Plan is a core benefit, and contributions are made by the College based on a formula using the employee's base annual salary. The College's contributions to the Plan in the years ended June 30, 2021 and 2020, were \$44.3 million and \$67.4 million, respectively. The assets of the Plan are administered by third parties.

15. Leases

The components of lease cost for the fiscal year ended June 30 were as follows (in thousands):

	2021	2020
Finance lease expense:		
Amortization of right-of-use assets	\$ 528	\$ 528
Interest on lease liabilities	22	30
Operating lease expense	13,079	15,040
Total lease cost	\$ 13,629	\$ 15,598
Other information:		
Cash paid for amounts included in the measurement of lease liabilities:		
Operating cash flows from finance leases	\$ 22	\$ 30
Operating cash flows from operating leases	12,393	14,486
Financing cash flows from finance leases	464	464
Right-of-use assets obtained in exchange for new operating lease liabilities	86	1,090
Weighted average remaining lease term – finance leases (in years)	2.75	3.75
Weighted average remaining lease term – operating leases (in years)	11.5	12.35
Weighted discount rate – finance leases	1.76%	1.76%
Weighted discount rate – operating leases	1.94%	1.93%

The annual payments based on maturities are reported under Commitments and Contingencies (see Note 16).

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

16. Commitments and Contingencies

Leases

Annual payments based on maturities of the College's leases as of June 30, 2021, are as follows (in thousands):

	Operating Leases	Finance Leases
2022	\$ 11,408	\$ 464
2023	11,328	464
2024	11,050	26
2025	10,914	–
2026	9,347	–
Thereafter	54,116	–
Total undiscounted lease payments	108,163	954
Less present value adjustment	(11,451)	(20)
Total discounted lease payments	<u>\$ 96,712</u>	<u>\$ 934</u>

Private Investments

The College has committed to invest in certain private investments over a period of time. The remaining private investment commitment as of June 30, 2021 and 2020, is \$269.3 million and \$303.0 million, respectively. Based on historical patterns, the College expects those amounts will be called into the partnerships for investment over the next three to five years and will be funded by assets of the endowment.

Self-Insurance Program for Professional Liability

Medical malpractice and other actions alleging wrongful conduct and seeking punitive damages are sometimes filed against physicians and the College's affiliated institutions. Since 1977, the College has maintained a medical malpractice self-insurance program (the Program) that until July 1, 2003, had been supplemented by reinsurance or excess insurance agreements with private insurance companies. Due to sharply increased costs, the College's favorable loss experience, and the positive effects of tort reform legislation, the College, effective July 1, 2003, elected not to

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

16. Commitments and Contingencies (continued)

purchase excess insurance coverage. To date, there has not been a settlement or jury verdict on a case that exceeded the self-insurance retention level that would have been required by the insurance market had the College decided to purchase coverage. The College continued to monitor the insurance market, and during fiscal year 2011, the College started purchasing reinsurance above a \$15 million self-insured retention. For the years ended June 30, 2021 and 2020, the College has purchased \$50 million in reinsurance above the \$15 million per occurrence and \$25 million aggregate self-insurance retention.

The Program's dedicated account is funded on a quasi-occurrence basis, meaning it is designed to cover the health care provider for an incident that happened while he or she was a participant no matter when the claim or lawsuit was filed, but if the incident upon which the claim or lawsuit is based was not reported to the College's Risk Management office, the matter would be asserted against the coverage in the fiscal year in which reporting occurred. Settlements, judgments, and costs of defense are paid from a pool of a self-insured retention, depending on the year the claim occurred or was filed; several layers of excess coverage are available to respond to them. Funding for the Program has been actuarially determined to the level of \$35 million per occurrence and \$70 million aggregate for payment of medical malpractice losses and related expenses. For the period from July 1, 2003 through September 1, 2010, all risk of loss is borne by the College.

The College has been named as a defendant in various claims for damages resulting from alleged medical malpractice. The malpractice reserve, which includes reserves for incurred but not reported claims, is \$45.9 million and \$38.8 million as of June 30, 2021 and 2020, respectively.

This liability was determined on a discounted basis without consideration of any insurance recoveries. The discount rate used in calculating the actuarial present value at June 30, 2021 and 2020, was 3% and 5% respectively.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

17. Transactions With Affiliates

Included among the College's Board of Trustees are members from the banking, insurance, and legal communities who provide assistance in the development of policies and programs for the College. Also, certain trustees, faculty, and staff of the College participate in the management of affiliated hospitals with which the College has contracts to provide services. During fiscal years 2021 and 2020, the College paid legal and other professional fees of approximately \$2.5 million and \$4.2 million, respectively, to law firms and other organizations with which several board members are affiliated. A portion of the College's pooled investments with a market value of \$111.9 million and \$79.8 million for fiscal years 2020 and 2021, respectively, was managed by an investment firm affiliated with a trustee. Also, the College has received, from time to time, significant contributions from various board members and corporations with which board members are affiliated. These transactions have been entered into in the normal course of business. The College also enters into transactions in the normal course of business with BSLMC and Baylor Genetics.

18. Financial Responsibility Standards

The Financial Responsibility Standards issued by the United States Department of Education (Department) require an institution to be financially responsible to participate in any Title IV, Higher Education Act program. In February 2020, the Department issued a revised financial responsibility rule that adopts new accounting standards and revises definitions and terminology to calculate the composite score ratios. The regulation is effective for financial statement filings that are submitted to the Department after July 1, 2020.

The notes supporting the Financial Responsibility Supplemental Schedule are presented below:

Note A

Net assets with donor restrictions, as reported on the consolidated balance sheets, are presented below:

Temporarily restricted net assets	\$ 658,878
Permanently restricted net assets	<u>483,003</u>
Total net assets with donor restrictions	<u><u>\$ 1,141,881</u></u>

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

18. Financial Responsibility Standards (continued)

Note B

Endowments with donor restrictions, as reported in Footnote 7: Endowment Funds, are presented below:

Temporarily restricted endowment	\$ 522,179
Permanently restricted endowment	458,174
Total endowment with donor restrictions	<u>980,353</u>

Note C

All debt obtained for long-term purposes, as reported on the consolidated balance sheets, is limited to the total net property, plant, and equipment for the expendable net assets calculation. The details are presented below:

Footnote 10: Bonds and Notes Payable	
Total outstanding balance of bonds and notes payable	\$ 588,906
Less deferred issuance costs	(4,366)
Plus original issue premium – 2012A Bond Series	–
Plus original issue premium – 2016 Bond Series	8,454
Total bonds and notes payable	<u>592,994</u>

Footnote 16: Commitments and Contingencies	
Lease liability – operating	96,712
Lease liability – financing	934
Total lease liability	<u>97,646</u>
All debt obtained for long-term purposes	<u>\$ 690,640</u>

Balance Sheet: Net property, plant, and equipment

Property and equipment, net	\$ 389,727
Plus leased right-to-use assets – operating	95,353
Total net property, plant, and equipment	<u>\$ 485,080</u>

All debt obtained for long-term purposes reported for the expendable net assets calculation is limited to \$485.1 million.

Baylor College of Medicine

Notes to Consolidated Financial Statements (continued)

18. Financial Responsibility Standards (continued)

Note D

Unsecured related-party receivables are a component of pledges receivable, as reported on the consolidated balance sheets:

Unsecured related-party receivables	\$ 10,020
Other pledges receivable	<u>32,064</u>
Total pledges receivable	<u>\$ 42,084</u>

Note E

For the purpose of calculating the total revenue without donor restrictions and gains without donor restrictions, the investment returns reported under both operating and nonoperating activities on the consolidated statement of activities are aggregated:

Operating – investment income, net of expenses	\$ 58,183
Nonoperating – investment income, net of distribution	<u>118,780</u>
Net investment income	<u>\$ 176,963</u>

Due to the aggregation of investment income, \$118.8 million is added to total operating revenue.

Note F

The College's postretirement benefit obligation at June 30, 2021, is \$7.1 million and is recorded in accounts payable and other liabilities of \$233.2 million.

Supplementary Information

Baylor College of Medicine

Financial Responsibility Supplemental Schedule
(In Thousands)

Primary Reserve Ratio

Expendable net assets:

Note	Financial Statement/ Footnote Disclosure	Line Item Description	Amount
	Consolidated balance sheets	Net assets without donor restrictions	\$ 491,208
	Consolidated balance sheets	Net assets with donor restrictions	1,141,881
Note A	See Note 18	Net assets with donor restrictions: restricted in perpetuity	(483,003)
Note B	See Note 18	Annuities, term endowments, and life income funds with donor restrictions	(522,179)
	Not applicable	Intangible assets	–
	Consolidated balance sheets	Net property, plant, and equipment	(389,727)
	Consolidated balance sheets	Leased right-to-use assets – operating	(95,353)
Note F	See Note 18	Post-employment and defined benefit pension liabilities	7,116
Note C	See Note 18	All debt obtained for long-term purposes, not to exceed total net property, plant, and equipment	485,080
Note D	See Note 18	Unsecured related-party receivables	(10,020)
		Expendable net assets	\$ 625,003

Total expenses without donor restrictions and losses without donor restrictions:

Note	Financial Statement/ Footnote Disclosure	Line Item Description	Amount
	Consolidated statement of activities	Total operating expenses	\$ 2,150,912
	Consolidated statement of activities	Nonoperating losses without donor restrictions: Other nonoperating activities	11,014
		Total expenses without donor restrictions and losses without donor restrictions	\$ 2,161,926

Baylor College of Medicine

Financial Responsibility Supplemental Schedule (continued)
(In Thousands)

Equity Ratio

Modified net assets:

Note	Financial Statement/ Footnote Disclosure	Line Item Description	Amount
	Consolidated balance sheets	Net assets without donor restrictions	\$ 491,208
	Consolidated balance sheets	Net assets with donor restrictions	1,141,881
	Not applicable	Intangible assets	-
Note D	See Note 18	Unsecured related-party receivables	(10,020)
		Modified net assets	<u>\$ 1,623,069</u>

Modified assets:

Note	Financial Statement/ Footnote Disclosure	Line Item Description	Amount
	Consolidated statement of activities	Total assets	\$ 2,986,434
	Not applicable	Intangible assets	-
Note D	See Note 18	Unsecured related-party receivables	(10,020)
		Modified assets	<u>\$ 2,976,414</u>

Baylor College of Medicine

Financial Responsibility Supplemental Schedule (continued)
(In Thousands)

Net Income Ratio

Change in net assets without donor restrictions:

Note	Financial Statement/ Footnote Disclosure	Line Item Description	Amount
	Consolidated statement of activities	Change in net assets without donor restrictions	\$ 132,432
		Change in net assets without donor restrictions	<u>\$ 132,432</u>

Total revenue without donor restrictions and gains without donor restrictions:

Note	Financial Statement/ Footnote Disclosure	Line Item Description	Amount
	Consolidated statement of activities	Total operating revenue	\$ 2,152,358
	Consolidated statement of activities	Nonoperating – gifts and pledges	671
	Consolidated statement of activities	Nonoperating – unrealized gain on interest rate swaps	20,751
	Consolidated statement of activities	Nonoperating – equity in earnings of unconsolidated affiliates – nonoperating	1,798
Note E	See Note 18	Nonoperating – investment income, net of distribution	118,780
		Total revenue without donor restrictions and gains without donor restrictions	<u>\$ 2,294,358</u>

Reports and Schedules Required by the Uniform Guidance



Ernst & Young LLP
1401 McKinney Street
Suite 2400
Houston, TX 77010

Tel: +1 713 750 1500
Fax: +1 713 750 1501
ey.com

Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance With *Government Auditing Standards*

The Management and The Board of Trustees
Baylor College of Medicine

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States, the financial statements of Baylor College of Medicine, which comprise the consolidated balance sheets as of June 30, 2021 and 2020, and the related consolidated statements of activities and cash flows for the years then ended, and the related notes to the financial statements, and have issued our report thereon dated October 15, 2021.

Internal Control Over Financial Reporting

In planning and performing our audit of the consolidated financial statements, we considered Baylor College of Medicine's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of Baylor College of Medicine's internal control. Accordingly, we do not express an opinion on the effectiveness of Baylor College of Medicine's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that have not been identified.

Compliance and Other Matters

As part of obtaining reasonable assurance about whether Baylor College of Medicine’s financial statements are free of material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of This Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity’s internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity’s internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Ernst + Young LLP

October 15, 2021



Ernst & Young LLP
1401 McKinney Street
Suite 2400
Houston, TX 77010

Tel: +1 713 750 1500
Fax: +1 713 750 1501
ey.com

Report of Independent Auditors on Compliance for Each Major Federal Program and Report on Internal Control Over Compliance Required by the Uniform Guidance

Management and The Board of Trustees
Baylor College of Medicine

Report on Compliance for Each Major Federal Program

We have audited Baylor College of Medicine's compliance with the types of compliance requirements described in the U.S. Office of Management and Budget (OMB) *Compliance Supplement* that could have a direct and material effect on each of Baylor College of Medicine's major federal programs for the year ended June 30, 2021. Baylor College of Medicine's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

Management's Responsibility

Management is responsible for compliance with federal statutes, regulations, and the terms and conditions of its federal awards applicable to its federal programs.

Auditor's Responsibility

Our responsibility is to express an opinion on compliance for each of Baylor College of Medicine's major federal programs based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. *Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Those standards and the Uniform Guidance require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about Baylor College of Medicine's compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for each major federal program. However, our audit does not provide a legal determination of Baylor College of Medicine's compliance.

Opinion on Each Major Federal Program

In our opinion, Baylor College of Medicine complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended June 30, 2021.

Other Matters

The results of our auditing procedures disclosed an instance of noncompliance, which is required to be reported in accordance with the Uniform Guidance and which is described in the accompanying schedule of findings and questioned costs and summarized in the table below. Our opinion on each major federal program is not modified with respect to this matter.

Finding No.	Assistance Listing No.	Program (or Cluster) Name	Compliance Requirement
2021-001	Various	Student Financial Assistance Cluster	Special Tests and Provisions

Baylor College of Medicine’s response to the noncompliance findings identified in our audit is described in the accompanying schedule of findings and questioned costs. Baylor College of Medicine’s response was not subjected to the auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

We performed audit procedures with respect to the Student Financial Assistance Cluster major federal program related to compliance requirements in Special Test and Provision N12, Gramm-Leach-Bliley Act – Student Information Security as outlined in the OMB Compliance Supplement for the year ended June 30, 2021. We determined whether Baylor College of Medicine has designated an individual to coordinate the information security program. We determined whether Baylor College of Medicine performed a risk assessment that addresses the three required areas noted in 16 CFR 314.4(b) and whether Baylor College of Medicine documented a safeguard for each risk identified from the three required to be risk assessed by 16 CFR 314.4(b). Our audit procedures did not evaluate whether the designated individual that coordinated the information security program is competent to oversee the program nor whether the individual possessed the adequate authority to carry out those duties. Our audit procedures also did not determine whether the risk assessment sufficiently addressed the required areas, whether the risks identified are the appropriate risks, or that the identified risks appear to be a complete list. Further, our audit procedures did not determine whether the documented safeguards have been put in place or that they will effectively mitigate, reduce, or even address the identified risks. Our opinion on the Student Financial Assistance Cluster major federal program is not modified with respect to this matter.

Report on Internal Control Over Compliance

Management of Baylor College of Medicine is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered Baylor College of Medicine’s internal control over compliance with the types of requirements that could have a direct and material effect on each major federal program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for each major federal program and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of Baylor College of Medicine’s internal control over compliance.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. *A material weakness in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. *A significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies and therefore, material weaknesses or significant deficiencies may exist that have not been identified. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, we did identify a deficiency in internal control over compliance, as described in the accompanying schedule of findings and questioned costs and summarized in the table below, that we consider to be a significant deficiency.

Finding No.	Assistance Listing No.	Program (or Cluster) Name	Compliance Requirement
2021-001	Various	Student Financial Assistance Cluster	Special Tests and Provisions

Baylor College of Medicine's response to the internal control over compliance finding identified in our audit is described in the accompanying schedule of findings and questioned costs. Baylor College of Medicine's response was not subjected to the auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Ernst + Young LLP

July 18, 2022

Baylor College of Medicine
Schedule of Expenditures of Federal Awards
Year Ended June 30, 2021

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing (ALN)	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF AGRICULTURE							
AGRICULTURAL RESEARCH-BASIC AND APPLIED RESEARCH	10.001		\$ 14,296,930	-	-	\$ 14,296,930	\$ 248,496
PASS-THROUGH AWARD FROM: PRAIRIE VIEW A&M 1890 INSTITUTION CAPACITY BUILDING GRANTS	10.216	2018-38821-27766	37,295	-	-	37,295	-
AGRICULTURE AND FOOD RESEARCH INITIATIVE (AFRI) PASS-THROUGH AWARD FROM: UNIVERSITY OF IDAHO	10.310		545,377	-	-	545,377	196,923
AGRICULTURE AND FOOD RESEARCH INITIATIVE (AFRI)	10.310	2017-67016-26301	(71)	-	-	(71)	-
	<i>Total ALN 10.310</i>		<u>545,306</u>	<u>-</u>	<u>-</u>	<u>545,306</u>	<u>196,923</u>
TOTAL DEPARTMENT OF AGRICULTURE			14,879,531	-	-	14,879,531	445,419
DEPARTMENT OF DEFENSE							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420		14,335,989	-	-	14,335,989	952,411
PASS-THROUGH AWARD FROM: BOSTON CHILDREN'S HOSPITAL							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT THE TRUSTEES OF BOSTON UNIVERSITY	12.420	W81XWH-17-1-0532	10,693	-	-	10,693	-
MILITARY MEDICAL RESEARCH AND DEVELOPMENT THE TRUSTEES OF BOSTON UNIVERSITY	12.420	W81XWH-13-2-0072	(1,456)	-	-	(1,456)	-
MILITARY MEDICAL RESEARCH AND DEVELOPMENT THE TRUSTEES OF COLUMBIA UNIVERSITY	12.420	W81XWH-17-1-0685	18,314	-	-	18,314	-
MILITARY MEDICAL RESEARCH AND DEVELOPMENT DUKE UNIVERSITY	12.420	W81XWH-17-1-0166	19,051	-	-	19,051	-
MILITARY MEDICAL RESEARCH AND DEVELOPMENT GEORGE WASHINGTON UNIVERSITY	12.420	W81XWH-14-1-0473	430	-	-	430	-
MILITARY MEDICAL RESEARCH AND DEVELOPMENT JOHNS HOPKINS UNIVERSITY	12.420	W81XWH-18-1-0672	314,844	-	-	314,844	-
MILITARY MEDICAL RESEARCH AND DEVELOPMENT JOHNS HOPKINS UNIVERSITY	12.420	W81XWH1910292	9,430	-	-	9,430	-
MILITARY MEDICAL RESEARCH AND DEVELOPMENT LOYOLA UNIVERSITY	12.420	W911QY-20-9-12	400,394	-	-	400,394	-
MILITARY MEDICAL RESEARCH AND DEVELOPMENT NORTHERN CALIFORNIA INSTITUTE FOR RESEARCH AND EDUCATION	12.420	W81XWH-19-1-0108	56,246	-	-	56,246	-
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-1-0558	16,779	-	-	16,779	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF DEFENSE (continued)							
PASS-THROUGH AWARD FROM (continued):							
<i>RESEARCH TRIANGLE INTERNATIONAL</i>							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-2-0077	\$ 52,749	\$ -	\$ -	\$ 52,749	\$ -
<i>RESEARCH TRIANGLE INTERNATIONAL</i>							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-2-0044	505,909	-	-	505,909	-
<i>RICE UNIVERSITY</i>							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	DARPA N6001-19-C-4020	275,464	-	-	275,464	-
<i>STATE UNIVERSITY OF NEW YORK</i>							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-2-0012	35,201	-	-	35,201	-
<i>TULANE UNIVERSITY</i>							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0026	335,779	-	-	335,779	-
<i>UNIVERSITY OF CALIFORNIA, BERKELEY</i>							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0586	1,885	-	-	1,885	-
<i>UNIVERSITY OF CALIFORNIA, SAN FRANCISCO</i>							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-14-2-0176	106,112	-	-	106,112	-
<i>UNIVERSITY OF CALIFORNIA, SAN FRANCISCO</i>							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-15-9-0001	215,774	-	-	215,774	-
<i>UNIVERSITY OF CALIFORNIA, SAN FRANCISCO</i>							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-2-0042	20,708	-	-	20,708	-
<i>UNIVERSITY OF CINCINNATI</i>							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-6-2-0020	7,013	-	-	7,013	-
<i>UNIVERSITY OF PITTSBURGH</i>							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-D-0024	69,043	-	-	69,043	2,729
<i>THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON</i>							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0537	34,156	-	-	34,156	-
<i>THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON</i>							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-20-1-0770	72,950	-	-	72,950	-
<i>THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER</i>							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0410	13,172	-	-	13,172	-
<i>WASHINGTON UNIVERSITY</i>							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-18-1-0084	181,491	-	-	181,491	-
<i>WILLIAM BEAUMONT HOSPITAL RESEARCH INSTITUTE</i>							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-16-1-0307	12,099	-	-	12,099	-
<i>WILLIAM BEAUMONT HOSPITAL RESEARCH INSTITUTE</i>							
MILITARY MEDICAL RESEARCH AND DEVELOPMENT	12.420	W81XWH-19-1-0288	91,512	-	-	91,512	-
<i>Total ALN 12.420</i>			17,211,731	-	-	17,211,731	955,140

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF DEFENSE (continued)							
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910		\$ 685,471	\$ -	\$ -	\$ 685,471	\$ 344,264
PASS-THROUGH AWARD FROM:							
THE TRUSTEES OF COLUMBIA UNIVERSITY							
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	N66001-17-C-4002	350,260	-	-	350,260	-
UNIVERSITY OF WISCONSIN							
RESEARCH AND TECHNOLOGY DEVELOPMENT	12.910	N66001-17-2-4010	243,524	-	-	243,524	-
		<i>Total ALN 12.910</i>	<u>1,279,255</u>	<u>-</u>	<u>-</u>	<u>1,279,255</u>	<u>344,264</u>
TOTAL DEPARTMENT OF DEFENSE			18,490,986	-	-	18,490,986	1,299,404
DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT							
LEAD-BASED PAINT HAZARD CONTROL IN PRIVATELY-OWNED HOUSING	14.900		267,482	-	-	267,482	25,534
TOTAL DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT			267,482	-	-	267,482	25,534
DEPARTMENT OF JUSTICE							
NATIONAL INSTITUTE OF JUSTICE RESEARCH, EVALUATION AND DEVELOPMENT							
PROJECT GRANTS	16.560		36,631	-	-	36,631	-
PASS-THROUGH AWARD FROM:							
OFFICE OF THE GOVERNOR							
CRIME VICTIM ASSISTANCE	16.575	3849301	-	-	59,107	59,107	-
COMMON SPIRIT HEALTH							
CRIME VICTIM ASSISTANCE	16.575	4065501	-	-	26,577	26,577	-
TOTAL DEPARTMENT OF JUSTICE			36,631	-	85,684	122,315	-
OCCUPATIONAL SAFETY AND HEALTH ADMINISTRATION							
OCCUPATIONAL SAFETY AND HEALTH SUSAN HARWOOD							
TRAINING GRANTS	17.502		70,711	-	-	70,711	-
TOTAL OCCUPATIONAL SAFETY AND HEALTH ADMINISTRATION			70,711	-	-	70,711	-
NATIONAL AERONAUTICS AND SPACE ADMINISTRATION							
EXPLORATION	43.003		19,056,609	-	-	19,056,609	14,290,527
PASS-THROUGH AWARD FROM:							
MASSACHUSETTS GENERAL HOSPITAL							
EXPLORATION	43.003	80NSSC20K0841	46,762	-	-	46,762	-
UNIVERSITY OF WASHINGTON							
EXPLORATION	43.003	NNX16AE78G	27,167	-	-	27,167	-
		<i>Total ALN 43.003</i>	<u>19,130,538</u>	<u>-</u>	<u>-</u>	<u>19,130,538</u>	<u>14,290,527</u>

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
NATIONAL AERONAUTICS AND SPACE ADMINISTRATION (continued)							
PASS-THROUGH AWARD FROM:							
CENTER FOR ADVANCEMENT OF SCIENCE IN SPACE							
SPACE OPERATIONS							
	43.007	GA-2018-270	\$ 203,818	\$ -	\$ -	\$ 203,818	\$ -
			203,818	-	-	203,818	-
			<u>19,334,356</u>	-	-	<u>19,334,356</u>	<u>14,290,527</u>
TOTAL NATIONAL AERONAUTICS AND SPACE ADMINISTRATION							
Total ALN 43.007							
NATIONAL ENDOWMENT FOR THE HUMANITIES							
PASS-THROUGH AWARD FROM:							
ASSOCIATION OF AMERICAN MEDICAL COLLEGES							
PROMOTION OF THE HUMANITIES TEACHING AND LEARNING RESOURCES							
AND CURRICULUM DEVELOPMENT							
	45.162	AH-268665	-	-	2,507	2,507	-
			-	-	2,507	2,507	-
TOTAL NATIONAL ENDOWMENT FOR THE HUMANITIES							
NATIONAL SCIENCE FOUNDATION							
ENGINEERING GRANTS							
	47.041		305,185	-	-	305,185	26,759
PASS-THROUGH AWARD FROM:							
TEXAS A&M UNIVERSITY							
ENGINEERING GRANTS							
	47.041	NSF-2037383	7,330	-	-	7,330	-
			312,515	-	-	312,515	26,759
			<u>312,515</u>	-	-	<u>312,515</u>	<u>26,759</u>
Total ALN 47.041							
MATHEMATICAL AND PHYSICAL SCIENCES							
	47.049		799,905	-	-	799,905	86,441
PASS-THROUGH AWARD FROM:							
RICE UNIVERSITY							
MATHEMATICAL AND PHYSICAL SCIENCES							
	47.049	PHY-1427654	13,540	-	-	13,540	-
RICE UNIVERSITY							
MATHEMATICAL AND PHYSICAL SCIENCES							
	47.049	PHY-2019745	420,550	-	-	420,550	-
NORTH CAROLINA STATE UNIVERSITY							
MATHEMATICAL AND PHYSICAL SCIENCES							
	47.049	NSF 2016-1551-01	4,706	-	-	4,706	-
UNIVERSITY OF HOUSTON							
MATHEMATICAL AND PHYSICAL SCIENCES							
	47.049	DBI-1707400	270,221	-	-	270,221	2,166
WASHINGTON UNIVERSITY							
MATHEMATICAL AND PHYSICAL SCIENCES							
	47.049	DGE-1745038	5,446	-	-	5,446	-
			1,514,368	-	-	1,514,368	88,607
			<u>1,514,368</u>	-	-	<u>1,514,368</u>	<u>88,607</u>
Total ALN 47.049							
COMPUTER AND INFORMATION SCIENCE AND ENGINEERING							
	47.070		632	-	-	632	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
NATIONAL SCIENCE FOUNDATION (continued)							
PASS-THROUGH AWARD FROM:							
RICE UNIVERSITY							
MATHEMATICAL AND PHYSICAL SCIENCES	47.070	CNS-1801865	\$ 9,978	\$ -	\$ -	\$ 9,978	\$ -
	<i>Total ALN 47.070</i>		10,610	-	-	10,610	-
BIOLOGICAL SCIENCES	47.074		107,762	-	-	107,762	-
COVID-19 BIOLOGICAL SCIENCES	47.074		196,889	-	-	196,889	-
PASS-THROUGH AWARD FROM:							
UNIVERSITY OF MICHIGAN							
BIOLOGICAL SCIENCES	47.074	NSF 1935265	114,044	-	-	114,044	-
RICE UNIVERSITY							
BIOLOGICAL SCIENCES	47.074	IOS-1856742	13,021	-	-	13,021	-
	<i>Total ALN 47.074</i>		431,716	-	-	431,716	-
SOCIAL, BEHAVIORAL, AND ECONOMIC SCIENCES	47.075		32,645	-	-	32,645	-
TOTAL NATIONAL SCIENCE FOUNDATION			2,301,854	-	-	2,301,854	115,366
DEPARTMENT OF EDUCATION							
FEDERAL WORK-STUDY PROGRAM	84.033		-	101,773	-	101,773	-
FEDERAL PERKINS LOAN PROGRAM – FEDERAL CAPITAL CONTRIBUTIONS	84.038		-	2,324,070	-	2,324,070	-
PASS-THROUGH AWARD FROM:							
HOUSTON INDEPENDENT SCHOOL DISTRICT							
MAGNET SCHOOLS ASSISTANCE	84.165	Rusk Academy	-	-	102,680	102,680	-
MAGNET SCHOOLS ASSISTANCE	84.165	Ryan Academy	-	-	132,057	132,057	-
	<i>Total ALN 84.165</i>		-	-	234,737	234,737	-
FEDERAL DIRECT STUDENT LOANS	84.268		-	18,832,957	-	18,832,957	-
EDUCATION STABILIZATION FUND							
COVID-19 HIGHER EDUCATION EMERGENCY RELIEF FUND (HEERF) STUDENT AID PORTION	84.425E		-	-	506,004	506,004	-
COVID-19 HEERF INSTITUTIONAL PORTION	84.425F		-	-	305,470	305,470	-
	<i>Total ALN 84.425</i>		-	-	811,474	811,474	-
TOTAL DEPARTMENT OF EDUCATION			-	21,258,800	1,046,211	22,305,011	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES							
PASS-THROUGH AWARD FROM:							
<i>ARKANSAS CHILDREN'S HOSPITAL</i>							
BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES - PREVENTION AND SURVEILLANCE	93.073	DD001285	\$ 29,410	\$ -	\$ -	\$ 29,410	\$ -
<i>THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON</i>							
BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES - PREVENTION AND SURVEILLANCE	93.073	DD004942	-	-	-	-	-
Total ALN 93.073			29,410	-	-	29,410	-
FAMILY SMOKING PREVENTION AND TOBACCO CONTROL ACT REGULATORY RESEARCH	93.077		321,012	-	-	321,012	103,293
PASS-THROUGH AWARD FROM:							
<i>THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON</i>							
BLOOD DISORDER PROGRAM: PREVENTION, SURVEILLANCE, AND RESEARCH	93.080	U27 DD001155	5,410	-	-	5,410	-
<i>THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON</i>							
BLOOD DISORDER PROGRAM: PREVENTION, SURVEILLANCE, AND RESEARCH	93.080	U27 DD000020	16,767	-	-	16,767	-
Total ALN 93.080			22,177	-	-	22,177	-
PREVENTION OF DISEASE, DISABILITY AND DEATH BY INFECTIOUS DISEASES	93.084		4,362	-	-	4,362	-
FOOD AND DRUG ADMINISTRATION-RESEARCH	93.103		1,466,144	-	-	1,466,144	752,747
PASS-THROUGH AWARD FROM:							
<i>JOHNS HOPKINS UNIVERSITY</i>							
FOOD AND DRUG ADMINISTRATION-RESEARCH	93.103	FD003898	2,787	-	-	2,787	-
<i>NEW YORK MEDICAL COLLEGE</i>							
FOOD AND DRUG ADMINISTRATION-RESEARCH	93.103	FD004090	18,337	-	-	18,337	-
Total ALN 93.103			1,487,268	-	-	1,487,268	752,747
PASS-THROUGH AWARD FROM:							
<i>CITY OF HOUSTON</i>							
COMPREHENSIVE COMMUNITY MENTAL HEALTH SERVICES FOR CHILDREN WITH SERIOUS EMOTIONAL DISORDER (SED)	93.104	SM082256	470,105	-	-	470,105	-
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110		-	-	739,737	739,737	-
PASS-THROUGH AWARD FROM:							
<i>THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON</i>							
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110	MC24051	-	-	1,185,000	1,185,000	-
MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS	93.110		-	-	24,626	24,626	-
Total ALN 93.110			-	-	1,949,363	1,949,363	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
ENVIRONMENTAL HEALTH	93.113		\$ 4,538,039	\$ -	\$ -	\$ 4,538,039	\$ 811,488
PASS-THROUGH AWARD FROM:							
<i>THE METHODIST HOSPITAL RESEARCH INSTITUTE</i>							
ENVIRONMENTAL HEALTH	93.113	ES031511	103,449	-	-	103,449	-
<i>THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON</i>							
ENVIRONMENTAL HEALTH	93.113	ES016302	31,514	-	-	31,514	-
<i>COLORADO STATE UNIVERSITY</i>							
ENVIRONMENTAL HEALTH	93.113	ES029766	4,019	-	-	4,019	-
<i>OREGON STATE UNIVERSITY</i>							
ENVIRONMENTAL HEALTH	93.113	ES029460	207	-	-	207	-
<i>UNIVERSITY OF ILLINOIS AT CHICAGO</i>							
ENVIRONMENTAL HEALTH	93.113	ES028615	203,603	-	-	203,603	-
	Total ALN 93.113		4,880,831	-	-	4,880,831	811,488
ORAL DISEASES AND DISORDERS RESEARCH	93.121		659,642	-	-	659,642	25,895
PASS-THROUGH AWARD FROM:							
<i>THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER</i>							
ORAL DISEASES AND DISORDERS RESEARCH	93.121	DE025248	3,161	-	-	3,161	-
<i>THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON</i>							
ORAL DISEASES AND DISORDERS RESEARCH	93.121	DE027794	64	-	-	64	-
<i>UNIVERSITY OF UTAH</i>							
ORAL DISEASES AND DISORDERS RESEARCH	93.121	DE027493	19,391	-	-	19,391	-
<i>RICE UNIVERSITY</i>							
ORAL DISEASES AND DISORDERS RESEARCH	93.121	DE021798	64,648	-	-	64,648	-
<i>FRED HUTCH CANCER RESEARCH</i>							
ORAL DISEASES AND DISORDERS RESEARCH	93.121	DE027850	49,486	-	-	49,486	-
	Total ALN 93.121		796,392	-	-	796,392	25,895
EMERGENCY MEDICAL SERVICES FOR CHILDREN	93.127		-	-	562,599	562,599	-
PASS-THROUGH AWARD FROM:							
<i>COLUMBIA UNIVERSITY</i>							
EMERGENCY MEDICAL SERVICES FOR CHILDREN	93.127	MC00007	-	-	122,704	122,704	-
<i>UNIVERSITY OF BUFFALO</i>							
EMERGENCY MEDICAL SERVICES FOR CHILDREN	93.127	MC33154	-	-	84,120	84,120	-
<i>UNIVERSITY OF TEXAS DELL MEDICAL SCHOOL</i>							
EMERGENCY MEDICAL SERVICES FOR CHILDREN	93.127	MC37471	-	-	216,001	216,001	-
<i>MEDICAL COLLEGE OF WISCONSIN</i>							
EMERGENCY MEDICAL SERVICES FOR CHILDREN	93.127	MC26201	-	-	(1,770)	(1,770)	-
	Total ALN 93.127		-	-	983,654	983,654	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136		\$ 95,312	\$ -	\$ -	\$ 95,312	\$ 1,863
PASS-THROUGH AWARD FROM:							
<i>HARRIS COUNTY</i>							
INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS	93.136	CE924976	32,745	-	-	32,745	-
Total ALN 93.136			128,057	-	-	128,057	1,863
NIEHS SUPERFUND HAZARDOUS SUBSTANCES - BASIC RESEARCH AND EDUCATION	93.143		1,873,615	-	-	1,873,615	666,235
PASS-THROUGH AWARD FROM:							
<i>TEXAS A&M UNIVERSITY</i>							
NIEHS SUPERFUND HAZARDOUS SUBSTANCES - BASIC RESEARCH AND EDUCATION	93.143	ES027704	195,528	-	-	195,528	-
<i>THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER</i>							
NIEHS SUPERFUND HAZARDOUS SUBSTANCES - BASIC RESEARCH AND EDUCATION	93.143	CA016672	2,227	-	-	2,227	-
Total ALN 93.143			2,071,370	-	-	2,071,370	666,235
PASS-THROUGH AWARD FROM:							
<i>UNIVERSITY OF NEW MEXICO</i>							
HIV-RELATED TRAINING AND TECHNICAL ASSISTANCE	93.145	HA33225	385,417	-	-	385,417	21,053
COVID-19 CENTERS OF EXCELLENCE	93.157		128,214	-	-	128,214	-
CENTERS OF EXCELLENCE	93.157		748,255	-	-	748,255	-
Total ALN 93.157			876,469	-	-	876,469	-
HUMAN GENOME RESEARCH	93.172		13,421,941	-	-	13,421,941	1,210,893
PASS-THROUGH AWARD FROM:							
<i>COLUMBIA UNIVERSITY</i>							
HUMAN GENOME RESEARCH	93.172	HG008972	61,905	-	-	61,905	-
<i>GEISINGER HEALTH SYSTEM</i>							
HUMAN GENOME RESEARCH	93.172	HG006834	5,999	-	-	5,999	-
<i>KAISER PERMANENTE</i>							
HUMAN GENOME RESEARCH	93.172	HG007292	69,950	-	-	69,950	-
<i>JOHNS HOPKINS UNIVERSITY</i>							
HUMAN GENOME RESEARCH	93.172	HG006542	620,418	-	-	620,418	-
<i>UNIVERSITY OF SOUTH CAROLINA</i>							
HUMAN GENOME RESEARCH	93.172	HG010925	7,039	-	-	7,039	-
<i>STANFORD UNIVERSITY</i>							
HUMAN GENOME RESEARCH	93.172	HG09649	1,220,439	-	-	1,220,439	-
<i>HARVARD MEDICAL SCHOOL</i>							
HUMAN GENOME RESEARCH	93.172	HG007530	135,713	-	-	135,713	-
Total ALN 93.172			15,543,404	-	-	15,543,404	1,210,893

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173		\$ 3,262,111	\$ -	\$ -	\$ 3,262,111	\$ 239,778
PASS-THROUGH AWARD FROM:							
<i>THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON</i>							
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	DC014589	27,888	-	-	27,888	-
<i>UNIVERSITY OF SOUTHERN CALIFORNIA</i>							
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	DC014450	15,251	-	-	15,251	-
<i>THE UNIVERSITY OF TEXAS AT AUSTIN</i>							
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	DC018579	22,761	-	-	22,761	-
<i>UNIVERSITY OF UTAH</i>							
RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS	93.173	DC014706	221	-	-	221	-
Total ALN 93.173			3,328,232	-	-	3,328,232	239,778
NATIONAL RESEARCH SERVICE AWARD IN PRIMARY CARE MEDICINE	93.186		175,904	-	-	175,904	-
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213		844,175	-	-	844,175	8,583
PASS-THROUGH AWARD FROM:							
<i>DUKE UNIVERSITY</i>							
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	AT009676	14,983	-	-	14,983	-
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	AT010961	32,894	-	-	32,894	-
<i>UNIVERSITY OF ALABAMA AT BIRMINGHAM</i>							
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	AT008621	4,981	-	-	4,981	-
<i>UNIVERSITY OF ARIZONA</i>							
RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH	93.213	AT008621	47,494	-	-	47,494	-
Total ALN 93.213			944,527	-	-	944,527	8,583
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226		2,603,583	-	-	2,603,583	197,826
PASS-THROUGH AWARD FROM:							
<i>UNIVERSITY OF MICHIGAN</i>							
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS024953	74,001	-	-	74,001	-
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS026622	36,995	-	-	36,995	-
<i>UNIVERSITY OF COLORADO</i>							
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS024597	964	-	-	964	-
PASS-THROUGH AWARD FROM:							
<i>UNIVERSITY OF HOUSTON</i>							
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.226	HS026790	8,746	-	-	8,746	-
Total ALN 93.226			2,724,289	-	-	2,724,289	197,826

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
NATIONAL CENTER ON SLEEP DISORDERS RESEARCH	93.233		\$ 550,407	\$ -	\$ -	\$ 550,407	\$ -
MENTAL HEALTH RESEARCH GRANTS	93.242		8,467,092	-	-	8,467,092	607,239
PASS-THROUGH AWARD FROM:							
ALLEN BRAIN INSTITUTE							
MENTAL HEALTH RESEARCH GRANTS	93.242	MH114830	391,015	-	-	391,015	64,198
CHILDREN'S HOSPITAL OF PHILADELPHIA	93.242	MH125958	12,581	-	-	12,581	-
UNIVERSITY OF COLORADO DENVER	93.242	MH121362	91,300	-	-	91,300	-
THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON	93.242	MH100930	120,683	-	-	120,683	-
UNIVERSITY OF SOUTH FLORIDA	93.242	MH107522	14,321	-	-	14,321	-
ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI	93.242	MH111932	(3,457)	-	-	(3,457)	-
UNIVERSITY OF TENNESSEE	93.242	MH112143	20,983	-	-	20,983	-
UNIVERSITY OF NORTH CAROLINA	93.242	MH104102	17,395	-	-	17,395	-
MENTAL HEALTH RESEARCH GRANTS	93.242	MH118249	28,768	-	-	28,768	-
MENTAL HEALTH RESEARCH GRANTS	93.242	MH124526	50,385	-	-	50,385	-
UNIVERSITY OF WISCONSIN	93.242	MH123422	106,863	-	-	106,863	-
MENTAL HEALTH RESEARCH GRANTS							
		Total ALN 93.242	9,317,929	-	-	9,317,929	671,437
SUBSTANCE ABUSE & MENTAL HEALTH SERVICES – PROJECTS OF REGIONAL & NATIONAL SIGNIFICANCE	93.243		-	-	932,029	932,029	-
SANTA MARIA HOSTEL							
SUBSTANCE ABUSE & MENTAL HEALTH SERVICES PROJECTS OF REGIONAL & NATIONAL SIGNIFICANCE	93.243	TI026362	-	-	18,004	18,004	-
BEHAVIORAL HEALTH SOLUTIONS							
SUBSTANCE ABUSE & MENTAL HEALTH SERVICES PROJECTS OF REGIONAL & NATIONAL SIGNIFICANCE	93.243	TI080684	-	-	85,657	85,657	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
<i>CENTER FOR RECOVERY AND WELLNESS RESOURCES</i>							
SUBSTANCE ABUSE & MENTAL HEALTH SERVICES PROJECTS OF REGIONAL & NATIONAL SIGNIFICANCE	93.243	TI026609	\$ -	\$ -	\$ (35)	\$ (35)	-
SUBSTANCE ABUSE & MENTAL HEALTH SERVICES PROJECTS OF REGIONAL & NATIONAL SIGNIFICANCE	93.243	TI080624	-	-	145,798	145,798	-
<i>THE UNIVERSITY OF TEXAS AT SAN ANTONIO</i>							
SUBSTANCE ABUSE & MENTAL HEALTH SERVICES PROJECTS OF REGIONAL & NATIONAL SIGNIFICANCE	93.243	TI026787	-	-	54,721	54,721	-
<i>CITY OF HOUSTON</i>							
SUBSTANCE ABUSE & MENTAL HEALTH SERVICES PROJECTS OF REGIONAL & NATIONAL SIGNIFICANCE	93.243	SP080300	-	-	29,506	29,506	-
Total ALN 93.243			-	-	1,265,680	1,265,680	-
OCCUPATIONAL SAFETY AND HEALTH PROGRAM	93.262		273,244	-	-	273,244	29,004
PASS-THROUGH AWARD FROM:							
<i>THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON</i>							
RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES	93.262	OH008421	5,170	-	-	5,170	-
Total ALN 93.262			278,414	-	-	278,414	29,004
ALCOHOL RESEARCH PROGRAMS	93.273		609,397	-	-	609,397	204,849
PASS-THROUGH AWARD FROM:							
<i>YALE UNIVERSITY</i>							
ALCOHOL RESEARCH PROGRAMS	93.273	AA020790	91,493	-	-	91,493	-
<i>UNIVERSITY OF HOUSTON</i>							
ALCOHOL RESEARCH PROGRAMS	93.273	AA023739	32,722	-	-	32,722	-
<i>UNIVERSITY OF LOUISVILLE</i>							
ALCOHOL RESEARCH PROGRAMS	93.273	AA026225	80,098	-	-	80,098	-
<i>SCRIPPS RESEARCH INSTITUTE</i>							
ALCOHOL RESEARCH PROGRAMS	93.273	AA021667	56,863	-	-	56,863	-
Total ALN 93.273			870,573	-	-	870,573	204,849

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279		\$ 80,743	\$ -	\$ -	\$ 80,743	\$ -
PASS-THROUGH AWARD FROM:							
<i>MASSACHUSETTS GENERAL HOSPITAL</i>							
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	DA047933	194,532	-	-	194,532	-
<i>SCRIPPS RESEARCH INSTITUTE</i>							
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	DA043268	3,541	-	-	3,541	-
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	DA046170	62,132	-	-	62,132	-
<i>UNIVERSITY OF IOWA</i>							
DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS	93.279	DA026437	24,872	-	-	24,872	-
Total ALN 93.279			365,820	-	-	365,820	-
DISCOVERY & APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH							
DISCOVERY & APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286		1,363,987	-	-	1,363,987	427,396
PASS-THROUGH AWARD FROM:							
<i>JOHNS HOPKINS UNIVERSITY</i>							
DISCOVERY & APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB028156	22,167	-	-	22,167	-
<i>RICE UNIVERSITY</i>							
DISCOVERY & APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	LM007093	43,644	-	-	43,644	-
DISCOVERY & APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB023431	1,982	-	-	1,982	-
<i>TEXAS A&M UNIVERSITY</i>							
DISCOVERY & APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB025945	32,734	-	-	32,734	-
DISCOVERY & APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB029064	27,227	-	-	27,227	-
<i>WAYNE STATE UNIVERSITY</i>							
DISCOVERY & APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH	93.286	EB026453	620,254	-	-	620,254	-
Total ALN 93.286			2,111,995	-	-	2,111,995	427,396

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307		\$ 967,084	\$ -	\$ -	\$ 967,084	\$ 164,004
PASS-THROUGH AWARD FROM:							
<i>UNIVERSITY OF ARIZONA</i>							
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD014127	11,751	-	-	11,751	-
<i>HOWARD UNIVERSITY</i>							
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD007597	9,331	-	-	9,331	-
<i>UNIVERSITY OF PITTSBURGH</i>							
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD009118	702	-	-	702	-
<i>TEXAS SOUTHERN UNIVERSITY</i>							
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD007605	10,053	-	-	10,053	-
<i>THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON</i>							
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD012942	(219)	-	-	(219)	-
<i>THE UNIVERSITY OF TEXAS AT AUSTIN</i>							
MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH	93.307	MD009675	3,681	-	-	3,681	-
		TOTAL ALN 93.307	1,002,383	-	-	1,002,383	164,004
TRANS-NIH RESEARCH SUPPORT	93.310		14,492,223	-	-	14,492,223	1,300,554
PASS-THROUGH AWARD FROM:							
<i>BETH ISRAEL DEACONESS MEDICAL CENTER</i>							
TRANS-NIH RESEARCH SUPPORT	93.310	TR002881	108,824	-	-	108,824	-
<i>THE UNIVERSITY OF TEXAS AT EL PASO</i>							
TRANS-NIH RESEARCH SUPPORT	93.310	GM118971	4,326	-	-	4,326	-
<i>HARVARD MEDICAL SCHOOL</i>							
TRANS-NIH RESEARCH SUPPORT	93.310	HG007530	149,837	-	-	149,837	-
<i>MASSACHUSETTS GENERAL HOSPITAL</i>							
TRANS-NIH RESEARCH SUPPORT	93.310	OD023253	3,992	-	-	3,992	-
<i>RICE UNIVERSITY</i>							
TRANS-NIH RESEARCH SUPPORT	93.310	HL151545	418,077	-	-	418,077	-
<i>UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN</i>							
TRANS-NIH RESEARCH SUPPORT	93.310	OD023272	37,197	-	-	37,197	-
		Total ALN 93.310	15,214,476	-	-	15,214,476	1,300,554
RARE DISORDERS: RESEARCH, SURVEILLANCE, HEALTH PROMOTION, AND EDUCATION	93.315		68,670	-	-	68,670	-
DIETARY SUPPLEMENT RESEARCH PROGRAM	93.321		140,401	-	-	140,401	140,401

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
STRENGTHENING PUBLIC HEALTH THROUGH SURVEILLANCE, EPIDEMIOLOGIC RESEARCH, DISEASE DETECTION AND PREVENTION	93.326		\$ 636,823	\$ -	\$ -	\$ 636,823	\$ -
COVID-19 STRENGTHENING PUBLIC HEALTH THROUGH SURVEILLANCE, EPIDEMIOLOGIC RESEARCH, DISEASE DETECTION AND PREVENTION	93.326		277,603	-	-	277,603	-
Total ALN 93.326			914,426	-	-	914,426	-
HEALTH PROFESSIONS STUDENT LOANS, INCLUDING PRIMARY CARE LOANS/ LOANS FOR DISADVANTAGED STUDENTS	93.342		-	457,371	-	457,371	-
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES PASS-THROUGH AWARD FROM:	93.350		(7,346)	-	-	(7,346)	(7,346)
<i>DYSTONIA MEDICAL RESEARCH FOUNDATION</i>							
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES DUKE UNIVERSITY	93.350	TR001456	55	-	-	55	-
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES HUDSONALPHA FOUNDATION	93.350	TR001803	30,523	-	-	30,523	-
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON	93.350	OD027070	16,037	-	-	16,037	-
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES WASHINGTON UNIVERSITY	93.350	TR003167	896	-	-	896	-
NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES	93.350	TR002764	55,261	-	-	55,261	-
Total ALN 93.350			95,426	-	-	95,426	(7,346)
RESEARCH INFRASTRUCTURE PROGRAMS	93.351		3,891,754	-	-	3,891,754	349,953
COVID-19 RESEARCH INFRASTRUCTURE PROGRAMS	93.351		447,493	-	-	447,493	-
PASS-THROUGH AWARD FROM:							
<i>UNIVERSITY OF CALIFORNIA, DAVIS</i>							
RESEARCH INFRASTRUCTURE PROGRAMS	93.351	OD023221	23,182	-	-	23,182	-
<i>UNIVERSITY OF WISCONSIN</i>							
RESEARCH INFRASTRUCTURE PROGRAMS	93.351	OD011106	34,397	-	-	34,397	-
<i>JOHNS HOPKINS UNIVERSITY</i>							
RESEARCH INFRASTRUCTURE PROGRAMS	93.351	OD026691	(2,425)	-	-	(2,425)	-
<i>HARVARD MEDICAL SCHOOL</i>							
RESEARCH INFRASTRUCTURE PROGRAMS	93.351	OD026435	119,923	-	-	119,923	-
Total ALN 93.351			4,514,324	-	-	4,514,324	349,953

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353		\$ 1,595,519	\$ -	\$ -	\$ 1,595,519	\$ 303,294
PASS-THROUGH AWARD FROM:							
<i>DANA-FARBER CANCER INSTITUTE</i>							
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	CA155258	45,512	-	-	45,512	-
<i>CHILDREN'S HOSPITAL OF PENNSYLVANIA</i>							
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	CA23568	677,274	-	-	677,274	17,899
<i>FRED HUTCHINSON CANCER CENTER</i>							
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	CA154967	5,467	-	-	5,467	-
<i>THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER</i>							
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	DE028233	186,657	-	-	186,657	-
<i>UNIVERSITY OF UTAH</i>							
21ST CENTURY CURES ACT - BEAU BIDEN CANCER MOONSHOT	93.353	CA224076	479,313	-	-	479,313	-
	Total ALN 93.353		2,989,742	-	-	2,989,742	321,193
NURSING RESEARCH							
93.361			1,924,927	-	-	1,924,927	680,652
PASS-THROUGH AWARD FROM:							
<i>UNIVERSITY OF MICHIGAN</i>							
NURSING RESEARCH	93.361	NR013658	72,717	-	-	72,717	30,067
<i>UNIVERSITY OF IOWA</i>							
NURSING RESEARCH	93.361	NR017610	282,941	-	-	282,941	-
<i>THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON</i>							
NURSING RESEARCH	93.361	NR013707	(4,213)	-	-	(4,213)	-
NURSING RESEARCH	93.361	NR017837	36,311	-	-	36,311	-
	Total ALN 93.361		2,312,683	-	-	2,312,683	710,719
21ST CENTURY CURES ACT - PRECISION MEDICINE INITIATIVE	93.368		22,989,898	-	-	22,989,898	1,962,613
CANCER CAUSE AND PREVENTION RESEARCH							
93.393			9,324,006	-	-	9,324,006	2,811,193
PASS-THROUGH AWARD FROM:							
<i>OREGON HEALTH & SCIENCE</i>							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA217842	396,925	-	-	396,925	-
<i>CITY OF HOPE RESEARCH INSTITUTE</i>							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA242218	58,721	-	-	58,721	-
<i>DARTMOUTH COLLEGE</i>							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA243449	19,664	-	-	19,664	-
<i>GEORGE WASHINGTON UNIVERSITY</i>							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA199336	192,186	-	-	192,186	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
<i>UNIVERSITY OF CALIFORNIA, SAN FRANCISCO</i>							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA181255	\$ (3)	\$ -	\$ -	(3)	-
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA214253	209,225	-	-	209,225	-
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA225478	16,705	-	-	16,705	-
<i>ST JUDE CHILDREN'S RESEARCH HOSPITAL</i>							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA187079	(927)	-	-	(927)	-
<i>VANDERBILT UNIVERSITY</i>							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA203012	220,949	-	-	220,949	-
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA225005	17,248	-	-	17,248	-
<i>STANFORD UNIVERSITY</i>							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA217105	192,859	-	-	192,859	-
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA232754	31,484	-	-	31,484	-
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA226081	8,592	-	-	8,592	-
<i>THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER</i>							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA186566	50,556	-	-	50,556	-
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA219463	15,415	-	-	15,415	-
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA239342	9,388	-	-	9,388	-
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA231141	226,984	-	-	226,984	-
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA219896	95,482	-	-	95,482	-
<i>COLUMBIA UNIVERSITY</i>							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA199336	18,170	-	-	18,170	-
<i>THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER</i>							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA212008	161,481	-	-	161,481	-
<i>ARIZONA STATE UNIVERSITY</i>							
CANCER CAUSE AND PREVENTION RESEARCH	93.393	CA237118	307,576	-	-	307,576	-
	Total ALN 93.393		11,572,686	-	-	11,572,686	2,811,193
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394		4,821,799	-	-	4,821,799	1,849,110
PASS-THROUGH AWARD FROM:							
<i>THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER</i>							
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA194733	739	-	-	739	-
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA200468	57,655	-	-	57,655	-
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA214263	109,979	-	-	109,979	-
<i>CHILDREN'S HOSPITAL OF PENNSYLVANIA</i>							
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA193776	73,792	-	-	73,792	42,288
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA193478	641	-	-	641	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
<i>DANA-FARBER CANCER INSTITUTE</i>							
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA230503	\$ 37,768	\$ -	\$ -	\$ 37,768	\$ -
<i>THE HOUSTON METHODIST RESEARCH INSTITUTE</i>							
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA211861	6,464	-	-	6,464	-
<i>FRED HUTCHINSON CANCER RESEARCH CENTER</i>							
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA214172	48,767	-	-	48,767	-
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA230144	16,130	-	-	16,130	-
<i>RICE UNIVERSITY</i>							
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA249367	10,759	-	-	10,759	-
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA255894	10,117	-	-	10,117	-
<i>WASHINGTON UNIVERSITY</i>							
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	MC27865	18,380	-	-	18,380	-
<i>THE UNIVERSITY OF TEXAS AT AUSTIN</i>							
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA229068	27,929	-	-	27,929	-
<i>NATIONWIDE CHILDREN'S HOSPITAL</i>							
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA196173	3,346	-	-	3,346	-
<i>NSABP</i>							
CANCER DETECTION AND DIAGNOSIS RESEARCH	93.394	CA196067	86,667	-	-	86,667	-
	Total ALN 93.394		5,330,932	-	-	5,330,932	1,891,398
CANCER TREATMENT RESEARCH	93.395		4,237,188	-	-	4,237,188	679,325
PASS-THROUGH AWARD FROM:							
<i>NEW YORK UNIVERSITY</i>							
CANCER TREATMENT RESEARCH	93.395	CA176502	(2,222)	-	-	(2,222)	-
<i>ST JUDE CHILDREN'S RESEARCH HOSPITAL</i>							
CANCER TREATMENT RESEARCH	93.395	CA081457	59,283	-	-	59,283	-
<i>UNIVERSITY OF MINNESOTA</i>							
CANCER TREATMENT RESEARCH	93.395	CA239701	55,697	-	-	55,697	-
<i>TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER</i>							
CANCER TREATMENT RESEARCH	93.395	CA221957	28,256	-	-	28,256	-
<i>UNIVERSITY OF CALIFORNIA, LOS ANGELES</i>							
CANCER TREATMENT RESEARCH	93.395	CA121947	31,773	-	-	31,773	-
<i>DUKE UNIVERSITY</i>							
CANCER TREATMENT RESEARCH	93.395	NS096096	112,234	-	-	112,234	-
<i>THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER</i>							
CANCER TREATMENT RESEARCH	93.395	CA208535	151,451	-	-	151,451	-
CANCER TREATMENT RESEARCH	93.395	CA235620	198,626	-	-	198,626	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
<i>MEDICAL COLLEGE OF WISCONSIN</i>							
CANCER TREATMENT RESEARCH	93.395	CA215403	\$ 1	\$ -	\$ -	\$ 1	\$ -
<i>NRG ONCOLOGY FOUNDATION, INC</i>							
CANCER TREATMENT RESEARCH	93.395	CA180868	6,244	-	-	6,244	-
<i>OREGON HEALTH AND SCIENCE UNIVERSITY</i>							
CANCER TREATMENT RESEARCH	93.395	CA180888	9,899	-	-	9,899	-
<i>SEATTLE CHILDREN'S RESEARCH INSTITUTE</i>							
CANCER TREATMENT RESEARCH	93.395	CA222486	134,631	-	-	134,631	-
<i>UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL</i>							
CANCER TREATMENT RESEARCH	93.395	CA218442	50,854	-	-	50,854	-
<i>CHILDREN'S HOSPITAL OF PHILADELPHIA</i>							
CANCER TREATMENT RESEARCH	93.395	CA196854	9,416	-	-	9,416	-
CANCER TREATMENT RESEARCH	93.395	CA212190	563	-	-	563	-
CANCER TREATMENT RESEARCH	93.395	CA180886	507,562	-	-	507,562	-
CANCER TREATMENT RESEARCH	93.395	CA097452	27,754	-	-	27,754	-
CANCER TREATMENT RESEARCH	93.395	AALL07P1	(4,021)	-	-	(4,021)	-
CANCER TREATMENT RESEARCH	93.395	CA211996	700	-	-	700	-
CANCER TREATMENT RESEARCH	93.395	CA228823	62,088	-	-	62,088	-
CANCER TREATMENT RESEARCH	93.395	CA233249	133,034	-	-	133,034	-
CANCER TREATMENT RESEARCH	93.395	CA189955	15,006	-	-	15,006	-
		Total ALN 93.395	5,826,017	-	-	5,826,017	679,325
CANCER BIOLOGY RESEARCH	93.396		11,480,667	-	-	11,480,667	664,227
PASS-THROUGH AWARD FROM:							
<i>THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER</i>							
CANCER BIOLOGY RESEARCH	93.396	CA174798	92,447	-	-	92,447	-
CANCER BIOLOGY RESEARCH	93.396	CA240526	6,187	-	-	6,187	-
CANCER BIOLOGY RESEARCH	93.396	CA184208	12	-	-	12	-
CANCER BIOLOGY RESEARCH	93.396	CA236781	5,180	-	-	5,180	-
<i>DARTMOUTH COLLEGE</i>							
CANCER BIOLOGY RESEARCH	93.396	CA225028	9,461	-	-	9,461	-
<i>GEORGIA TECH UNIVERSITY</i>							
CANCER BIOLOGY RESEARCH	93.396	CA218664	39,898	-	-	39,898	-
<i>LURIE CHILDREN'S HOSPITAL OF CHICAGO</i>							
CANCER BIOLOGY RESEARCH	93.396	CA217613	51,678	-	-	51,678	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
<i>THE METHODIST HOSPITAL RESEARCH INSTITUTE</i>							
CANCER BIOLOGY RESEARCH	93.396	CA193362	\$ 7,824	\$ -	\$ -	\$ 7,824	\$ -
CANCER BIOLOGY RESEARCH	93.396	CA253553	195,836	-	-	195,836	-
<i>MOUNT SINAI SCHOOL</i>							
CANCER BIOLOGY RESEARCH	93.396	CA154947	20,739	-	-	20,739	-
<i>UNIVERSITY OF CALIFORNIA, IRVINE</i>							
CANCER BIOLOGY RESEARCH	93.396	CA228140	41,966	-	-	41,966	-
<i>UNIVERSITY OF COLORADO DENVER</i>							
CANCER BIOLOGY RESEARCH	93.396	CA224867	332,727	-	-	332,727	-
<i>THE UNIVERSITY OF NORTH CAROLINA</i>							
CANCER BIOLOGY RESEARCH	93.396	CA148761	143,743	-	-	143,743	-
<i>UNIVERSITY OF NEW MEXICO</i>							
CANCER BIOLOGY RESEARCH	93.396	CA206980	147,033	-	-	147,033	-
<i>UNIVERSITY OF WASHINGTON</i>							
CANCER BIOLOGY RESEARCH	93.396	CA190378	(63)	-	-	(63)	-
	Total ALN 93.396		12,575,335	-	-	12,575,335	664,227
CANCER CENTERS SUPPORT GRANTS	93.397		8,328,378	-	-	8,328,378	353,059
COVID-19 CANCER CENTERS SUPPORT GRANTS	93.397		331,400	-	-	331,400	-
PASS-THROUGH AWARD FROM:							
<i>THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER</i>							
CANCER CENTERS SUPPORT GRANTS	93.397	CA127001	174,193	-	-	174,193	-
CANCER CENTERS SUPPORT GRANTS	93.397	CA140388	(1,563)	-	-	(1,563)	-
CANCER CENTERS SUPPORT GRANTS	93.397	CA217333	51,428	-	-	51,428	-
CANCER CENTERS SUPPORT GRANTS	93.397	CA221707	47,288	-	-	47,288	-
<i>SOUTHWEST ONCOLOGY GROUP</i>							
CANCER CENTERS SUPPORT GRANTS	93.397	CA180888	79,117	-	-	79,117	-
<i>SARCOMA ALLIANCE FOR RESEARCH THROUGH COLLABORATION (SARC SPORE)</i>							
CANCER CENTERS SUPPORT GRANTS	93.397	CA168512	(2,025)	-	-	(2,025)	-
	Total ALN 93.397		9,008,216	-	-	9,008,216	353,059
CANCER RESEARCH MANPOWER	93.398		1,747,724	-	-	1,747,724	-
PASS-THROUGH AWARD FROM:							
<i>CEDARS-SINAI MEDICAL CENTER</i>							
CANCER RESEARCH MANPOWER	93.398	CA247257	16,000	-	-	16,000	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
<i>RICE UNIVERSITY</i>							
CANCER RESEARCH MANPOWER	93.398	CA213994	\$ 8,358	\$ -	\$ -	\$ 8,358	\$ -
CANCER RESEARCH MANPOWER	93.398	CA213878	20,923	-	-	20,923	-
Total ALN 93.398			1,793,005	-	-	1,793,005	-
PASS-THROUGH AWARD FROM:							
<i>CHILDREN'S HOSPITAL OF PHILADELPHIA</i>							
CANCER RESEARCH MANPOWER	93.399	CA189955	68,226	-	-	68,226	-
<i>NSABP</i>							
CANCER CONTROL	93.399	FB-13	28,559	-	-	28,559	-
CANCER CONTROL	93.399	CA12027 #TFED41S2EXT-714	162	-	-	162	-
Total ALN 93.399			96,947	-	-	96,947	-
PASS-THROUGH AWARD FROM:							
<i>UNIVERSITY OF VERMONT</i>							
COVID-19 STRENGTHENING PUBLIC HEALTH SYSTEMS AND SERVICES THROUGH NATIONAL PARTNERSHIPS TO IMPROVE AND PROTECT THE NATION'S HEALTH	93.421	NU38OT000280-03-02	-	-	61,690	61,690	-
PASS-THROUGH AWARD FROM:							
<i>TIRR MEMORIAL HERMANN</i>							
ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING AND REHABILITATION RESEARCH	93.433	90S15027-01	11,170	-	-	11,170	-
COVID-19 CLAIMS REIMBURSEMENT TO HEALTH CARE PROVIDERS AND FACILITIES FOR TESTING, TREATMENT AND VACCINE ADMINISTRATION FOR THE UNINSURED	93.461		-	-	2,257,496	2,257,496	-
COVID-19 PROVIDER RELIEF FUND	93.498		-	-	3,524,875	3,524,875	-
PASS-THROUGH AWARD FROM:							
<i>TEXAS DEPARTMENT OF FAMILY AND PROTECTIVE SERVICES</i>							
TEMPORARY ASSISTANCE FOR NEEDY FAMILIES	93.558	529-16-0003-00003	-	-	696,220	696,220	-
<i>TEXAS COUNCIL FOR DEVELOPMENTAL DISABILITIES</i>							
DEVELOPMENTAL DISABILITIES BASIC SUPPORT AND ADVOCACY GRANTS	93.630	19111	-	-	(1,199)	(1,199)	-
DEVELOPMENTAL DISABILITIES BASIC SUPPORT AND ADVOCACY GRANTS	93.630	20211	-	-	178,284	178,284	-
DEVELOPMENTAL DISABILITIES BASIC SUPPORT AND ADVOCACY GRANTS	93.630	20212	-	-	74,490	74,490	-
Total ALN 93.630			-	-	251,575	251,575	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM:							
<i>HARRIS HEALTH SYSTEM</i>							
MATERNAL OPIOID MISUSE MODEL	93.687	CMS331766	\$ -	\$ -	\$ 68,740	\$ 68,740	\$ -
MENTAL AND BEHAVIORAL HEALTH EDUCATION AND TRAINING GRANTS	93.732		13,098	-	-	13,098	-
PASS-THROUGH AWARD FROM:							
<i>UNIVERSITY OF HOUSTON</i>							
CENTERS FOR MEDICARE AND MEDICAID SERVICES (CMS) RESEARCH, DEMONSTRATIONS AND EVALUATIONS	93.779	CMS331751	40,051	-	-	40,051	-
CARDIOVASCULAR DISEASES RESEARCH	93.837		11,394,910	-	-	11,394,910	918,548
PASS-THROUGH AWARD FROM:							
<i>THE BRIGHAM & WOMEN'S HOSPITAL, INC</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL148218	13,010	-	-	13,010	-
<i>CITY OF HOPE RESEARCH INSTITUTE</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL152932	44,308	-	-	44,308	-
<i>DUKE UNIVERSITY</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL134510	25,805	-	-	25,805	-
<i>THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL132401	685	-	-	685	-
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL145487	6,670	-	-	6,670	-
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL156059	63,611	-	-	63,611	-
<i>OHIO STATE UNIVERSITY</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL134824	195,948	-	-	195,948	-
<i>UNIVERSITY OF COLORADO</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL147064	10,246	-	-	10,246	-
<i>BOSTON VA RESEARCH INSTITUTE</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL130163	50	-	-	50	-
<i>UNIVERSITY OF ARIZONA</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL136528	7,939	-	-	7,939	-
<i>EAST CAROLINA UNIVERSITY</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL142544	136,759	-	-	136,759	-
<i>JOHNS HOPKINS UNIVERSITY</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL096812	180,118	-	-	180,118	-
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL146907	196,277	-	-	196,277	-
<i>MASSACHUSETTS GENERAL HOSPITAL</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL123336	2,715	-	-	2,715	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
<i>PENNSYLVANIA STATE UNIVERSITY</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL137763	\$ 114,362	\$ -	\$ -	\$ 114,362	\$ -
<i>UNIVERSITY OF HOUSTON</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL146745	265,472	-	-	265,472	-
<i>UNIVERSITY OF CALIFORNIA, SAN FRANCISCO</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL126146	2,224	-	-	2,224	-
<i>UNIVERSITY OF BUFFALO</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL137558	50,474	-	-	50,474	-
<i>UNIVERSITY OF MICHIGAN</i>							
COVID-19 CARDIOVASCULAR DISEASES RESEARCH	93.837	HL156812	27,757	-	-	27,757	-
<i>UNIVERSITY OF NORTH CAROLINA</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL152034	23,000	-	-	23,000	-
<i>TEXAS A & M UNIVERSITY</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL134780	80,406	-	-	80,406	-
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL146852	122,430	-	-	122,430	-
<i>EMORY UNIVERSITY</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL128566	2,813	-	-	2,813	-
<i>INDIANA UNIVERSITY</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL123767	(9,013)	-	-	(9,013)	-
<i>THE METHODIST HOSPITAL RESEARCH INSTITUTE</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL129767	1,804	-	-	1,804	-
<i>UNIVERSITY OF ALABAMA AT BIRMINGHAM</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL120338	55,709	-	-	55,709	-
<i>UNIVERSITY OF WISCONSIN</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL149404	25,275	-	-	25,275	-
<i>NEW ENGLAND RESEARCH INSTITUTES, INC</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL107407	277	-	-	277	-
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL068270	2,815	-	-	2,815	-
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL135691	108,621	-	-	108,621	-
<i>RICE UNIVERSITY</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL140305	148,786	-	-	148,786	-
<i>YALE UNIVERSITY</i>							
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL125918	8,033	-	-	8,033	-
CARDIOVASCULAR DISEASES RESEARCH	93.837	HL141852	86,397	-	-	86,397	-
Total ALN 93.837			13,396,693	-	-	13,396,693	918,548

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
LUNG DISEASES RESEARCH	93.838		\$ 2,681,873	\$ -	\$ -	\$ 2,681,873	\$ 67,763
PASS-THROUGH AWARD FROM:							
<i>NATIONAL JEWISH MEDICAL AND RESEARCH CENTER</i>							
LUNG DISEASES RESEARCH	93.838	HL089897	75,767	-	-	75,767	-
<i>UNIVERSITY OF CALIFORNIA, SAN FRANCISCO</i>							
LUNG DISEASES RESEARCH	93.838	HL139717	44,568	-	-	44,568	-
<i>UNIVERSITY OF NORTH TEXAS</i>							
LUNG DISEASES RESEARCH	93.838	20-312-0217571-66102L	92,460	-	-	92,460	24,525
<i>UNIVERSITY OF ALABAMA AT BIRMINGHAM</i>							
LUNG DISEASES RESEARCH	93.838	HL133232	19,799	-	-	19,799	-
<i>THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER</i>							
LUNG DISEASES RESEARCH	93.838	HL130129	7,646	-	-	7,646	-
<i>THE UNIVERSITY OF TEXAS MEDICAL BRANCH AT GALVESTON</i>							
LUNG DISEASES RESEARCH	93.838	HL145477	262,249	-	-	262,249	-
<i>INDIANA UNIVERSITY</i>							
LUNG DISEASES RESEARCH	93.838	HL148247	26,376	-	-	26,376	-
<i>YALE UNIVERSITY</i>							
LUNG DISEASES RESEARCH	93.838	HL145567	61,860	-	-	61,860	-
<i>COPD FOUNDATION</i>							
LUNG DISEASES RESEARCH	93.838	HL128954	2,219	-	-	2,219	-
Total ALN 93.838			3,274,817	-	-	3,274,817	92,288
BLOOD DISEASES AND RESOURCES RESEARCH	93.839		3,434,987	-	-	3,434,987	261,348
PASS-THROUGH AWARD FROM:							
<i>THOMAS JEFFERSON UNIVERSITY</i>							
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL128234	(1,818)	-	-	(1,818)	-
<i>CHILDRENS HOSPITAL MEDICAL CENTER, CINCINNATI</i>							
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL133883	18,721	-	-	18,721	-
<i>CHILDREN'S HOSPITAL OF PHILADELPHIA</i>							
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL148054	201	-	-	201	-
<i>UNIVERSITY OF UTAH</i>							
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL102482	(31,540)	-	-	(31,540)	-
<i>BOSTON CHILDREN'S HOSPITAL</i>							
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL133384	2,004	-	-	2,004	-
<i>THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER</i>							
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL124112	111,954	-	-	111,954	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
<i>BLOOD WORKS NORTHWEST</i>							
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL125957	\$ 9,958	\$ -	\$ -	\$ 9,958	\$ -
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL152200	34,208	-	-	34,208	-
<i>RUTGERS UNIVERSITY</i>							
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL133817	5,489	-	-	5,489	-
<i>UNIVERSITY OF HOUSTON</i>							
BLOOD DISEASES AND RESOURCES RESEARCH	93.839	HL151858	118,056	-	-	118,056	-
	Total ALN 93.839		3,702,220	-	-	3,702,220	261,348
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846		5,973,331	-	-	5,973,331	1,515,167
PASS-THROUGH AWARD FROM:							
<i>RICE UNIVERSITY</i>							
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR071258	20,025	-	-	20,025	-
<i>VANDERBILT UNIVERSITY</i>							
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR072483	5,329	-	-	5,329	-
PASS-THROUGH AWARD FROM (continued):							
<i>THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON</i>							
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR075380	18,753	-	-	18,753	-
<i>UNIVERSITY OF MICHIGAN</i>							
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR078073	14,279	-	-	14,279	-
<i>UNIVERSITY OF MINNESOTA</i>							
ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH	93.846	AR042423	29,616	-	-	29,616	-
	Total ALN 93.846		6,061,333	-	-	6,061,333	1,515,167
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847		25,855,233	-	-	25,855,233	4,511,312
PASS-THROUGH AWARD FROM:							
<i>UNIVERSITY OF IOWA</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK118752	1,225	-	-	1,225	-
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK108328	40,327	-	-	40,327	-
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK108334	24,484	-	-	24,484	-
<i>THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK116378	95,623	-	-	95,623	-
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK114235	15,692	-	-	15,692	-
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK126042	129,329	-	-	129,329	-
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK122708	10,667	-	-	10,667	-
<i>ARBOR RESEARCH COLLABORATIVE</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK062456	2,888	-	-	2,888	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
<i>BETH ISRAEL DEACONESS MEDICAL CENTER</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK112886	\$ 4,465	\$ -	\$ -	\$ 4,465	\$ -
<i>CHILDREN'S HOSPITAL COLORADO</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK99999	907	-	-	907	-
<i>CHILDREN'S NATIONAL MEDICAL CENTER</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK102561	79,833	-	-	79,833	-
<i>CEDARS-SINAI MEDICAL CENTER</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK109588	41,373	-	-	41,373	-
<i>CASE WESTERN RESERVE UNIVERSITY</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK118290	162,544	-	-	162,544	-
<i>UNIVERSITY OF UTAH</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	CA224076	14,720	-	-	14,720	-
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK114456	40,257	-	-	40,257	-
<i>ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK119200	19,172	-	-	19,172	-
<i>UNIVERSITY OF COLORADO</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK090964	15,236	-	-	15,236	-
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK072493	106,410	-	-	106,410	-
<i>UNIVERSITY OF COLORADO DENVER</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK117001	23,735	-	-	23,735	-
<i>UNIVERSITY OF MICHIGAN</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK101108	331	-	-	331	-
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK062456	39,981	-	-	39,981	-
<i>JOHNS HOPKINS UNIVERSITY</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK061730	5,258	-	-	5,258	-
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK089174	20,221	-	-	20,221	-
<i>GEORGE WASHINGTON UNIVERSITY</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK061230	28,171	-	-	28,171	-
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK098246	438,118	-	-	438,118	-
<i>SAINT LOUIS UNIVERSITY</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK061718	186,598	-	-	186,598	-
<i>THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK100866	6,747	-	-	6,747	-
<i>RUTGERS UNIVERSITY</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK112365	62,438	-	-	62,438	-
<i>UNIVERSITY OF ARIZONA</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK106462	9,634	-	-	9,634	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
<i>SEATTLE CHILDREN'S RESEARCH</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK121224	\$ 246,265	\$ -	\$ -	\$ 246,265	\$ -
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK113005	175,741	-	-	175,741	-
<i>UNIVERSITY OF MARYLAND</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK061425	123,332	-	-	123,332	-
<i>UNIVERSITY OF CALIFORNIA, LOS ANGELES</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK122013	674	-	-	674	-
<i>UNIVERSITY OF CALIFORNIA, SAN DIEGO</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK097771	238,488	-	-	238,488	-
<i>THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK115761	177,509	-	-	177,509	-
<i>THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK108328	90,615	-	-	90,615	-
<i>VANDERBILT UNIVERSITY</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK111831	149,477	-	-	149,477	-
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK124845	41,880	-	-	41,880	-
<i>CHILDREN'S HOSPITAL OF PHILADELPHIA</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK066174	4,030	-	-	4,030	-
<i>CHILDRENS HOSPITAL MEDICAL CENTER, CINCINNATI</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK103117	123,334	-	-	123,334	-
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK072493	14,482	-	-	14,482	-
<i>UNIVERSITY OF WASHINGTON</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK092202	1,756	-	-	1,756	-
<i>UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK090964	71,411	-	-	71,411	-
<i>UNIVERSITY OF HOUSTON</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK117476	39,937	-	-	39,937	-
<i>UNIVERSITY OF PENNSYLVANIA</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK060990	54,804	-	-	54,804	-
<i>AMERICAN PSYCHOLOGICAL ASSOCIATION</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK118763	22,904	-	-	22,904	-
<i>UNIVERSITY OF SOUTH FLORIDA</i>							
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK124166	68,944	-	-	68,944	-
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK124789	18,759	-	-	18,759	-
DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH	93.847	DK117483	84,235	-	-	84,235	-
Total ALN 93.847			29,230,194	-	-	29,230,194	4,511,312

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853		\$ 22,729,906	\$ -	\$ -	22,729,906	\$ 3,002,410
PASS-THROUGH AWARD FROM:							
<i>THE BRIGHAM & WOMEN'S HOSPITAL, INC</i>							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS113890	17,247	-	-	17,247	-
<i>CHILDREN'S HOSPITAL OF PHILADELPHIA</i>							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS115052	39,543	-	-	39,543	-
<i>THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON</i>							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS098981	2,508	-	-	2,508	-
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS090405	18,703	-	-	18,703	-
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS103592	218,864	-	-	218,864	-
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS110806	95,266	-	-	95,266	-
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS115886	10,895	-	-	10,895	-
<i>COLUMBIA UNIVERSITY</i>							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS098976	18,836	-	-	18,836	-
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS078059	3,002	-	-	3,002	-
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	MS089674	4,477	-	-	4,477	-
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS073872	29	-	-	29	-
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS110826	10,204	-	-	10,204	-
<i>EMORY UNIVERSITY</i>							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS51630	(11,642)	-	-	(11,642)	-
<i>HARVARD MEDICAL SCHOOL</i>							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS118402	64,886	-	-	64,886	-
<i>JOHNS HOPKINS UNIVERSITY</i>							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS102920	981	-	-	981	-
<i>KENNEDY KRIEGER INSTITUTE</i>							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS098482	118,025	-	-	118,025	-
<i>NORTHWESTERN UNIVERSITY</i>							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS108874	125,633	-	-	125,633	-
<i>TEXAS A&M UNIVERSITY</i>							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS094535	(19,313)	-	-	(19,313)	-
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS106907	35,717	-	-	35,717	-
<i>UNIVERSITY OF MICHIGAN</i>							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS099340	19,314	-	-	19,314	-
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS099046	135,824	-	-	135,824	-
<i>DUKE UNIVERSITY</i>							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS112917	297,101	-	-	297,101	-
<i>MAYO CLINIC</i>							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS115198	25,499	-	-	25,499	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
<i>THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER</i>							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS112280	\$ 19,916	\$ -	\$ -	\$ 19,916	\$ -
<i>UNIVERSITY OF CINCINNATI</i>							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS095869	779	-	-	779	-
<i>UNIVERSITY OF DELAWARE</i>							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS111310	33,108	-	-	33,108	-
<i>UNIVERSITY OF HOUSTON</i>							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS112497	37,309	-	-	37,309	-
<i>UNIVERSITY OF LOUISVILLE</i>							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS114982	12,358	-	-	12,358	-
<i>UNIVERSITY OF ROCHESTER</i>							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS118246	41,504	-	-	41,504	-
<i>UNIVERSITY OF UTAH</i>							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS107486	793	-	-	793	-
<i>UNIVERSITY OF VIRGINIA</i>							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS088034	25,046	-	-	25,046	-
<i>UNIVERSITY OF WISCONSIN</i>							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS115102	180,594	-	-	180,594	-
<i>WILLIAMS BONE MARROW TRANSPLANT HOSPITAL</i>							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS110838	9,824	-	-	9,824	-
<i>UNIVERSITY OF CALIFORNIA, SAN FRANCISCO</i>							
EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES & NEUROLOGICAL DISORDERS	93.853	NS086090	(10,021)	-	-	(10,021)	-
Total ALN 93.853			24,312,715	-	-	24,312,715	3,002,410
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		15,717,992	-	-	15,717,992	1,617,271
COVID-19 ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855		6,839,494	-	-	6,839,494	1,578,660
PASS-THROUGH AWARD FROM:							
<i>BENAROYA RESEARCH INSTITUTE</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI109565	16,136	-	-	16,136	-
<i>CREIGHTON UNIVERSITY</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI48219	70,301	-	-	70,301	-
<i>EAST CAROLINA UNIVERSITY</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI146930	82,349	-	-	82,349	-
<i>FAMILY HEALTH INTERNATIONAL</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI068619	31,326	-	-	31,326	-
<i>VANDERBILT UNIVERSITY</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI125135	53,048	-	-	53,048	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
<i>WASHINGTON UNIVERSITY</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI077810	\$ 804	\$ -	\$ -	\$ 804	\$ -
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI141716	257,725	-	-	257,725	-
<i>UNIVERSITY OF UTAH</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI125301	80,497	-	-	80,497	-
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI136963	27,083	-	-	27,083	-
<i>YALE UNIVERSITY</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI089992	42,233	-	-	42,233	-
<i>EMORY UNIVERSITY</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI148684	27,370	-	-	27,370	-
COVID-19 ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI148684	92,569	-	-	92,569	-
<i>DUKE UNIVERSITY</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI104681	4,910	-	-	4,910	-
<i>MASSACHUSETTS GENERAL HOSPITAL</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI127507	6,505	-	-	6,505	-
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI134940	-	-	-	-	-
<i>THE METHODIST HOSPITAL RESEARCH INSTITUTE</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI120749	12,144	-	-	12,144	-
<i>THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI055449	35,573	-	-	35,573	-
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI116208	9,101	-	-	9,101	-
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	GM120011	29,653	-	-	29,653	-
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI152999	462,835	-	-	462,835	-
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI151259	114,747	-	-	114,747	-
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI143229	46,679	-	-	46,679	-
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI141349	131,504	-	-	131,504	-
<i>COLUMBIA UNIVERSITY</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI20989	32,724	-	-	32,724	-
<i>UNIVERSITY OF CALIFORNIA, SAN FRANCISCO</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI082973	1,859	-	-	1,859	-
<i>UNIVERSITY OF CALIFORNIA, SAN DIEGO</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI069536	151,483	-	-	151,483	-
COVID-19 ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI069536	41,123	-	-	41,123	-
<i>UNIVERSITY OF NORTH CAROLINA</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI050410	9,102	-	-	9,102	-
<i>UNIVERSITY OF PITTSBURGH</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI032539	83,497	-	-	83,497	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
<i>TEXAS A&M HEALTH SCIENCE CENTER</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI144459	\$ 5,909	\$ -	\$ -	\$ 5,909	\$ -
<i>TEXAS TECH UNIVERSITY</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI135197	40,789	-	-	40,789	-
<i>TUFTS UNIVERSITY</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI121401	1,048	-	-	1,048	-
<i>UNIVERSITY OF HOUSTON</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI122418	5,682	-	-	5,682	-
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI133697	40,594	-	-	40,594	-
<i>JOHNS HOPKINS UNIVERSITY</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI068632	169,114	-	-	169,114	-
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI130836	430,059	-	-	430,059	-
<i>CHILDREN'S HOSPITAL OF BOSTON</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI084011	1,252	-	-	1,252	-
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI126614	142,322	-	-	142,322	-
<i>NEW YORK BLOOD CENTER</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI078314	60,954	-	-	60,954	-
<i>CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI117804	29,736	-	-	29,736	-
<i>NEW YORK STATE HEALTH</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AL14489101	88,504	-	-	88,504	-
<i>THE UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER</i>							
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI105135	5,215	-	-	5,215	-
ALLERGY AND INFECTIOUS DISEASES RESEARCH	93.855	AI154597	73,433	-	-	73,433	-
Total ALN 93.855			25,606,977	-	-	25,606,977	3,195,931
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859		14,075,819	-	-	14,075,819	637,275
PASS-THROUGH AWARD FROM:							
<i>UNIVERSITY OF CALIFORNIA, BERKELEY</i>							
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM063210	1,746	-	-	1,746	-
<i>THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON</i>							
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM120011	45,498	-	-	45,498	-
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM072804	31,040	-	-	31,040	-
<i>SANFORD BURNHAM MEDICAL RESEARCH INSTITUTE</i>							
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM121203	46,850	-	-	46,850	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
<i>THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER</i>							
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM127332	\$ 88,411	\$ -	\$ -	\$ 88,411	\$ -
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM098200	6,773	-	-	6,773	-
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	HD030284	34,490	-	-	34,490	-
<i>PACIFIC NORTHWEST RESEARCH INSTITUTE</i>							
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM132589	26,988	-	-	26,988	-
<i>TEXAS A&M UNIVERSITY</i>							
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM132436	85,788	-	-	85,788	-
<i>UNIVERSITY OF MICHIGAN</i>							
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	AI150470	148,901	-	-	148,901	-
<i>UNIVERSITY OF ILLINOIS</i>							
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM115111	(14)	-	-	(14)	-
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM136384	40,257	-	-	40,257	-
<i>UNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN</i>							
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM082837	79,096	-	-	79,096	-
<i>COLUMBIA UNIVERSITY</i>							
BIOMEDICAL RESEARCH AND RESEARCH TRAINING	93.859	GM119396	123,564	-	-	123,564	-
	Total ALN 93.859		14,835,207	-	-	14,835,207	637,275
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		20,609,685	-	-	20,609,685	2,798,868
COVID-19 CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865		66,018	-	-	66,018	-
PASS-THROUGH AWARD FROM:							
<i>ARIZONA STATE UNIVERSITY</i>							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD095380	6,632	-	-	6,632	-
<i>UNIVERSITY OF NORTH CAROLINA</i>							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD086139	2,094	-	-	2,094	-
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD089880	58,848	-	-	58,848	-
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD089881	245,705	-	-	245,705	-
<i>COLUMBIA UNIVERSITY</i>							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD055651	418,026	-	-	418,026	-
<i>CHILDREN'S NATIONAL MEDICAL CENTER</i>							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD099131	3,514	-	-	3,514	-
<i>CHILDREN'S RESEARCH INSTITUTE</i>							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD061221	206,610	-	-	206,610	-
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD094213	25,889	-	-	25,889	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
<i>THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL</i>							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD095976	\$ 743	\$ -	\$ -	\$ 743	\$ -
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD091347	27,254	-	-	27,254	-
<i>UNIVERSITY OF ALABAMA AT BIRMINGHAM</i>							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD061222	28,166	-	-	28,166	-
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD086851	(4,187)	-	-	(4,187)	-
<i>PENNSYLVANIA STATE UNIVERSITY</i>							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD089922	1,138	-	-	1,138	-
<i>PRESIDENT AND FELLOWS OF HARVARD COLLEGE ON BEHALF OF HARVARD MEDICAL SCHOOL</i>							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD052102	162,407	-	-	162,407	-
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD103133	291,414	-	-	291,414	-
<i>WASHINGTON UNIVERSITY</i>							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD070855	7,415	-	-	7,415	-
<i>WEILL MEDICAL COLLEGE</i>							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD067244	353,858	-	-	353,858	81,034
<i>UNIVERSITY OF CALIFORNIA, LOS ANGELES</i>							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD092471	912	-	-	912	-
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD095548	3,033	-	-	3,033	-
<i>INDIANA UNIVERSITY</i>							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD090215	(327)	-	-	(327)	-
<i>UNIVERSITY OF COLORADO DENVER</i>							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD098415	9,569	-	-	9,569	-
<i>UNIVERSITY OF HOUSTON</i>							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD099242	17,678	-	-	17,678	-
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD095520	124,382	-	-	124,382	-
<i>UNIVERSITY OF WISCONSIN</i>							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD102172	46,891	-	-	46,891	-
<i>THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON</i>							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD093660	138,391	-	-	138,391	-
<i>UNIVERSITY OF MICHIGAN</i>							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HD085233	557	-	-	557	-
<i>THE BRIGHAM & WOMEN'S HOSPITAL, INC</i>							
CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH	93.865	HG009922	112,001	-	-	112,001	-
Total ALN 93.865			22,964,316	-	-	22,964,316	2,879,902

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
AGING RESEARCH	93.866		\$ 12,722,822	\$ -	\$ -	\$ 12,722,822	\$ 1,131,004
COVID-19 AGING RESEARCH	93.866		133,569	-	-	133,569	-
PASS-THROUGH AWARD FROM:							
<i>EMORY UNIVERSITY</i>							
AGING RESEARCH	93.866	AG061357	259,318	-	-	259,318	-
AGING RESEARCH	93.866	AG065187	126,175	-	-	126,175	-
AGING RESEARCH	93.866	AG065815	50,263	-	-	50,263	-
<i>BOSTON UNIVERSITY</i>							
AGING RESEARCH	93.866	AG058589	544,234	-	-	544,234	-
<i>STANFORD UNIVERSITY</i>							
AGING RESEARCH	93.866	AG036695	943,101	-	-	943,101	262,107
<i>MASSACHUSETTS GENERAL HOSPITAL</i>							
AGING RESEARCH	93.866	AG064413	7,273	-	-	7,273	-
<i>OHIO STATE UNIVERSITY</i>							
AGING RESEARCH	93.866	AG058822	2,165	-	-	2,165	-
<i>RICE UNIVERSITY</i>							
AGING RESEARCH	93.866	AG061597	11,512	-	-	11,512	-
AGING RESEARCH	93.866	AG062690	21,066	-	-	21,066	-
<i>TEXAS A&M UNIVERSITY</i>							
AGING RESEARCH	93.866	AG061726	24,898	-	-	24,898	-
<i>WAKE FOREST UNIVERSITY HEALTH SCIENCES</i>							
AGING RESEARCH	93.866	AG062689	358,694	-	-	358,694	-
AGING RESEARCH	93.866	AG064440	13,323	-	-	13,323	-
<i>UNIVERSITY OF HOUSTON</i>							
AGING RESEARCH	93.866	AG065170	33,752	-	-	33,752	-
<i>THE UNIVERSITY OF TEXAS AT SAN ANTONIO</i>							
AGING RESEARCH	93.866	AG052409	101,728	-	-	101,728	-
<i>UNIVERSITY OF SOUTHERN CALIFORNIA</i>							
AGING RESEARCH	93.866	AG010483	15,366	-	-	15,366	-
AGING RESEARCH	93.866	AG041845	7,176	-	-	7,176	-
AGING RESEARCH	93.866	AG024904	2,400	-	-	2,400	-
AGING RESEARCH	93.866	AG063689	16,453	-	-	16,453	-
AGING RESEARCH	93.866	AG061848	1,345	-	-	1,345	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
<i>THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON</i>							
AGING RESEARCH	93.866	AG069466	\$ 23,009	\$ -	\$ -	\$ 23,009	\$ -
AGING RESEARCH	93.866	AG058463	216,023	-	-	216,023	-
AGING RESEARCH	93.866	AG060413	688	-	-	688	-
AGING RESEARCH	93.866	AG061901	82,208	-	-	82,208	-
AGING RESEARCH	93.866	AG061646	1,019	-	-	1,019	-
	Total ALN 93.866		15,719,580	-	-	15,719,580	1,393,111
VISION RESEARCH	93.867		9,861,041	-	-	9,861,041	1,082,140
PASS-THROUGH AWARD FROM:							
<i>JAEB CENTER FOR HEALTH RESEARCH FOUNDATION, INC</i>							
VISION RESEARCH	93.867	EY11751	41,386	-	-	41,386	-
VISION RESEARCH	93.867	EY14231	45,035	-	-	45,035	-
<i>CLEVELAND CLINIC FOUNDATION</i>							
VISION RESEARCH	93.867	EY031087	53,235	-	-	53,235	-
<i>NEW YORK UNIVERSITY</i>							
VISION RESEARCH	93.867	EY026869	9,884	-	-	9,884	-
COVID-19 VISION RESEARCH	93.867	EY026869	1,066	-	-	1,066	-
<i>TEXAS A&M UNIVERSITY</i>							
VISION RESEARCH	93.867	EY029695	165,306	-	-	165,306	-
<i>UNIVERSITY OF MIAMI</i>							
VISION RESEARCH	93.867	EY028764	9,493	-	-	9,493	-
PASS-THROUGH AWARD FROM:							
<i>UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER</i>							
VISION RESEARCH	93.867	EY026999	18,191	-	-	18,191	-
<i>UNIVERSITY OF WASHINGTON</i>							
VISION RESEARCH	93.867	EY025181	(142)	-	-	(142)	-
	Total ALN 93.867		10,204,495	-	-	10,204,495	1,082,140
MEDICAL LIBRARY ASSISTANCE	93.879		84,870	-	-	84,870	30,377
PASS-THROUGH AWARD FROM:							
<i>RICE UNIVERSITY</i>							
MEDICAL LIBRARY ASSISTANCE	93.879	LM007093	94,538	-	-	94,538	-
	Total ALN 93.879		179,408	-	-	179,408	30,377

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM:							
UNIVERSITY HOSPITALS CLEVELAND MEDICAL CENTER NATIONAL BIOTERRORISM HOSPITAL PREPAREDNESS PROGRAM	93.889	U3REP190615	\$ 54,257	\$ -	\$ -	\$ 54,257	\$ -
REACH UP, INC HEALTHY START INITIATIVE	93.926	H49MC12793	35,683	-	-	35,683	-
TEXAS DEPARTMENT OF STATE HEALTH SERVICES HIV PREVENTION ACTIVITIES_HEALTH DEPARTMENT BASED	93.940	HS000077800010	-	-	172,365	172,365	-
TUBERCULOSIS DEMONSTRATION, RESEARCH, PUBLIC AND PROFESSIONAL EDUCATION	93.947		37,373	-	-	37,373	-
PPHF GERIATRIC EDUCATION CENTERS	93.969		748,587	-	-	748,587	270,040
COVID-19 PPHF GERIATRIC EDUCATION CENTERS	93.969		90,367	-	-	90,367	-
Total ALN 93.969			838,954	-	-	838,954	270,040
PRIMARY CARE MEDICINE AND DENTISTRY CLINICIAN EDUCATOR CAREER DEVELOPMENT AWARDS	93.976		92,523	-	-	92,523	-
INTERNATIONAL RESEARCH AND RESEARCH TRAINING	93.989		214,624	-	-	214,624	-
PASS-THROUGH AWARD FROM:							
TEXAS DEPARTMENT OF STATE HEALTH SERVICES MATERNAL AND CHILD HEALTH SERVICES BLOCK GRANT TO THE STATES	93.994	HHS000109600030	-	-	11,736	11,736	-
THE UNIVERSITY OF TEXAS AT AUSTIN (TEXAS DEPARTMENT OF STATE HEALTH SERVICES) MATERNAL AND CHILD HEALTH SERVICES BLOCK GRANT TO THE STATES	93.994	HHS0000115300001	-	-	103,907	103,907	-
Total ALN 93.994			-	-	115,643	115,643	-
PASS-THROUGH AWARD FROM:							
	93RD	AHRQ HHSA290201500002C	94,217	-	-	94,217	-
	93RD	CDC #75D30119C05322	7,604	-	-	7,604	-
	93RD	CDC-200-2017-95100	32	-	-	32	-
	93RD	HHSN2682016000151	519,941	-	-	519,941	-
	93RD	HHSN2682016000331	2,660,509	-	-	2,660,509	-
	93RD	HHSN27200006-14-0100.B1C1D1.0036	6	-	-	6	6
	93RD	HHSN27200008-16-0017.B1C1D1.0043	5,382	-	-	5,382	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
	93RD	HHSN27200009-15-0020	\$ 29,458	\$ -	\$ -	29,458	\$ -
	93RD	HHSN27200012-16-0075	82,943	-	-	82,943	-
	93RD	HHSN27200014-16-0050	4,306	-	-	4,306	-
	93RD	HHSN27200015	44,852	-	-	44,852	8,629
	93RD	HHSN2720013-16-0057.C1D1.00 58	467,295	-	-	467,295	392,683
	93RD	HHSN2722013000151	143,961	-	-	143,961	-
	93RD	HHSN2722013-14	169,699	-	-	169,699	159,628
	93RD	NIAID HHSN2722017000131	127	-	-	127	-
	93RD	NIH 75N91019P00756	4,617	-	-	4,617	-
	93RD	NIH 75N93019P01211	648,539	-	-	648,539	-
	93RD	NIH 75N93020P01410	857,356	-	-	857,356	-
	93RD	75N93019F00071	30,466	-	-	30,466	-
	93RD	75N93019F00131	2,771	-	-	2,771	-
	93RD	75N93019F00132	49,539	-	-	49,539	-
PASS-THROUGH AWARD FROM:							
ATLANTA RESEARCH AND EDUCATION FOUNDATION	93RD	CDC 75D30119C04211	788,936	-	-	788,936	-
BOSTON CHILDREN'S HOSPITAL	93RD	CDC 75D30120C07725	10,033	-	-	10,033	-
BOSTON UNIVERSITY	93RD	HHSN261201500026C	11,137	-	-	11,137	-
CHILDREN'S HOSPITAL LOS ANGELES (CA209-9JY)	93RD	CA209-9JY	1,740	-	-	1,740	-
DUKE UNIVERSITY	93RD	HHSN2752010000031	125,678	-	-	125,678	-
EASTERN VIRGINIA MEDICAL SCHOOL	93RD	CDC-200-2016-91451	5,117	-	-	5,117	-
HENNEPIN RESEARCH INSTITUTE	93RD	75N-94019C00006	15,647	-	-	15,647	-
INTELLIGENCE ADVANCED RESEARCH PROJECTS ACTIVITY	93RD	D16PC00003	3,402,782	-	-	3,402,782	662,532
INTELLIGENCE ADVANCED RESEARCH PROJECTS ACTIVITY	93RD	2019-19071900001	180,103	-	-	180,103	-
MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH	93RD	U01DD001224	4,020	-	-	4,020	-
MEDSTAR RESEARCH INSTITUTE	93RD	HHSP2332015000221	281,525	-	-	281,525	-
NATIONAL MARROW DONOR PROGRAM	93RD	NUMBER 1702	22,332	-	-	22,332	-
NATIONAL MARROW DONOR PROGRAM	93RD	NUMBER 1705	278	-	-	278	-
NATIONAL MARROW DONOR PROGRAM	93RD	NUMBER 1801	3,401	-	-	3,401	-
NATIONAL MARROW DONOR PROGRAM	93RD	NUMBER 1802	3,960	-	-	3,960	-
NEW ENGLAND RESEARCH INSTITUTE	93RD	HHSN-2682012000	460	-	-	460	-
NEW ENGLAND RESEARCH INSTITUTE	93RD	U24HL135691	75	-	-	75	-
THE UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT HOUSTON	93RD	75D30118C02646	17,571	-	-	17,571	-
THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH	93RD	HG011711	14,773	-	-	14,773	-

Baylor College of Medicine

Schedule of Expenditures of Federal Awards (continued)

Federal Grantor/Pass-Through Grantor/Program Title	Assistance Listing Number	Pass-Through Entity/Other Identifying Number	Research and Development Cluster	Student Financial Assistance Cluster	Other Federal Expenditures	Total Federal Expenditures	Amounts Provided to Subrecipients
DEPARTMENT OF HEALTH AND HUMAN SERVICES (continued)							
PASS-THROUGH AWARD FROM (continued):							
UNIVERSITY OF ALABAMA AT BIRMINGHAM	93RD	HHSN272201600017C	\$ 2,234	\$ -	\$ -	\$ 2,234	\$ -
UNIVERSITY OF ALABAMA AT BIRMINGHAM	93RD	HHSN272201600018C	1,931	-	-	1,931	-
UNIVERSITY OF ALABAMA AT BIRMINGHAM	93RD	HHSN272201100035C	1,697	-	-	1,697	-
UNIVERSITY OF ALABAMA AT BIRMINGHAM	93RD	HHSN268201800005I	39,898	-	-	39,898	-
UNIVERSITY OF COLORADO DENVER	93RD	HHSF223201610046C	(25)	-	-	(25)	-
UNIVERSITY OF MICHIGAN	93RD	HHSN268201800002I	134,722	-	-	134,722	-
UNIVERSITY OF NEW MEXICO	93RD	HHSN75Q80120C00003	36,075	-	-	36,075	-
UNIVERSITY OF NORTH CAROLINA	93RD	HHSN268201700001I	308,459	-	-	308,459	-
UNIVERSITY OF SOUTH FLORIDA	93RD	NIDDK-TRIALNET	7,805	-	-	7,805	-
TOTAL DEPARTMENT OF HEALTH AND HUMAN SERVICES			326,201,603	457,371	11,347,301	338,006,275	37,726,960
EXECUTIVE OFFICE OF THE PRESIDENT							
PASS-THROUGH AWARD FROM:							
UNIVERSITY OF BALTIMORE							
RESEARCH AND DATA ANALYSIS	95.007	G1999ONDCP06A	111,573	-	-	111,573	17,500
RESEARCH AND DATA ANALYSIS	95.007	G1999ONDCP06A	(40)	-	-	(40)	-
TOTAL EXECUTIVE OFFICE OF THE PRESIDENT			111,533	-	-	111,533	17,500
DEPARTMENT OF HOMELAND SECURITY							
PASS-THROUGH AWARD FROM:							
HARRIS COUNTY							
DISASTER GRANTS - PUBLIC ASSISTANCE (PRESIDENTIALLY DECLARED DISASTERS)	97.036	SMARTPOD	-	-	59,507	59,507	-
COVID-19 DISASTER GRANTS - PUBLIC ASSISTANCE (PRESIDENTIALLY DECLARED DISASTERS)	97.036	SMARTPOD	-	-	833,060	833,060	-
DISASTER GRANTS - PUBLIC ASSISTANCE (PRESIDENTIALLY DECLARED DISASTERS)	97.036	SARS-CoV-2	-	-	14,703	14,703	-
Total ALN 97.036			-	-	907,270	907,270	-
PASS-THROUGH AWARD FROM:							
UNIVERSITY OF HOUSTON							
CENTERS FOR HOMELAND SECURITY	97.061	17STBT100001	23,124	-	-	23,124	-
TOTAL DEPARTMENT OF HOMELAND SECURITY			23,124	-	907,270	930,394	-
TOTAL EXPENDITURES OF FEDERAL AWARDS			\$ 381,717,811	\$ 21,716,171	\$ 13,388,973	\$ 416,822,955	\$ 53,920,710

See accompanying notes to schedule of expenditures of federal awards and schedule of expenditures of state awards.

Baylor College of Medicine

Notes to Schedule of Expenditures of Federal Awards

Year Ended June 30, 2021

1. Basis of Presentation

The accompanying schedule of expenditures of federal awards (the Schedule) presents a summary of the financial activities of Baylor College of Medicine (the College) for the year ended June 30, 2021, which have been funded by the federal government. The information in the Schedule is presented in accordance with the requirements of the Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Because the Schedule presents only federal expenditure activities of the College, they are not intended to and do not present the financial position, changes in net assets, or cash flows of the College as a whole.

2. Summary of Significant Accounting Policies

The Schedule has been prepared on a modified accrual basis of accounting and includes all expenditures of federal awards, direct and pass-through, received by the College from federal grantor agencies. Direct costs are charged to sponsored agreements on a cash basis except for salaries and fringe benefits that are charged on an accrual basis. Indirect costs are expensed against sponsored agreements at the close of the month in which the direct costs are charged and, therefore, are a combination of modified accrual and cash basis accounting. Federal awards are deemed to be expended when the College incurs the expenses. Such expenditures are recognized following the cost principles contained in OMB Circular A-21, *Cost Principles for Educational Institutions*, or the Uniform Guidance, as applicable, wherein certain types of expenditures are not allowable or are limited as to reimbursement. Federal direct programs and pass-through programs are presented by federal department and, where applicable, the funding agency within the department and the pass-through entity.

3. Federal Awards Classification

The expenditures of federal awards presented in this Schedule were identified pursuant to the definition of federal awards promulgated in OMB Circular A-21, *Cost Principles for Educational Institutions*, or the Uniform Guidance. Federal awards include all federal financial assistance and federal cost-reimbursement contracts received directly from federal awarding agencies or indirectly from pass-through entities. The federal awards have been classified by program according to award objective and federal awarding agency.

Baylor College of Medicine

Notes to Schedule of Expenditures of Federal Awards (continued)

4. Administered Federal Loan Programs

Outstanding loans under administered federal loan programs as of June 30, 2021, were as follows:

	Assistance Listing Number	Outstanding Balance June 30, 2021
Federal Perkins Loan Program	84.038	\$ 1,517,543
Health Professions Student Loans, Including Primary Care Loans, Loans for Disadvantaged Students (Health Professions Student Loans)	93.342	369,108

Total disbursements for student financial assistance loan programs administered by the College on behalf of the Department of Health and Human Services and the Department of Education for the fiscal year ended June 30, 2021, are identified below.

	Assistance Listing Number	FY 2021 Disbursements
Federal Perkins Loan Program	84.038	\$ —
Health Professions Student Loans	93.342	—

5. Federal Direct Student Loans Program

The College participated in the Federal Direct Student Loans Program (CFDA 84.268), including Unsubsidized Stafford Loans and PLUS Loans. The College was not the recipient of the funds. The programs are considered as a component of the student financial assistance cluster. Loan disbursements under the programs for the year ended June 30, 2021, totaled \$18,832,957.

Baylor College of Medicine

Notes to Schedule of Expenditures of Federal Awards (continued)

6. COVID-19 Provider Relief Fund (Assistance Listing No. 93.498)

The Schedule includes \$3,524,875 received from the U.S. Department of Health and Human Services (HHS) between April 10, 2020 and June 30, 2020, under the Provider Relief Fund (PRF) program of Assistance Listing No. 93.498. In accordance with guidance from HHS, these amounts are presented as Period 1 in the HHS PRF Reporting Portal. Such amounts were recognized as other revenue on Baylor College of Medicine’s consolidated statements of activities for the years ended June 30, 2021 and 2020. Due to the PRF Reporting Portal requirements, this amount is not the total PRF received and/or recognized by the College as other revenue in the consolidated financial statements for the year ended June 30, 2021.

The amount presented on the Schedule for PRF is for the fiscal year ended June 30, 2021. The amount presented reconciles to the PRF information reported to HHS, as follows:

Name of Subsidiary for HHS Reporting Period 1 Provider Relief Fund Report	Billing Tax Identification Number (TIN) of Subsidiary	Type of Distribution	Total Other Provider Relief Fund Expenses Reported
Baylor College of Medicine (faculty group practice)	300791563	General	\$ 3,070,896
Baylor College of Medicine	741613878	General	300,129
Community Pathology Associates	760421006	General	112,286
Baylor Pathology Consultants	760495836	General	27,050
Baylor Dermatopathology Lab	760495837	General	14,514
			<u>\$ 3,524,875</u>

Baylor College of Medicine

Schedule of Findings and Questioned Costs

Year Ended June 30, 2021

Section I – Summary of Auditor’s Results

Financial Statements

Type of auditor’s report issued on whether the financial statements audited were prepared in accordance with GAAP:

Unmodified

Internal control over financial reporting:

Material weakness(es) identified? Yes X No

Significant deficiency(ies) identified? Yes X None reported

Noncompliance material to financial statements noted? Yes X No

Federal Awards

Internal control over major federal programs:

Material weakness(es) identified? Yes X No

Significant deficiency(ies) identified? X Yes None reported

Type of auditor’s report issued on compliance for major federal programs:

Unmodified

Any audit findings disclosed that are required to be reported in accordance with Section 2 CFR 200.516(a)?

 X Yes No

Baylor College of Medicine

Schedule of Findings and Questioned Costs (continued)

Section I – Summary of Auditors’ Results (continued)

<u>Assistance Listing Number(s)</u>	<u>Name of Federal Program or Cluster</u>
Identification of major federal programs:	
Various Assistance Listings	Research and Development Cluster
84.033, 84.038, 84.268, 93.342	Student Financial Assistance Cluster
93.498	COVID-19 Provider Relief Fund
84.425E/84.425F	COVID-19 Higher Education Emergency Relief Fund (HEERF) Student Aid Portion and Institutional Portion

Dollar threshold to distinguish between Type A and Type B state programs \$3,000,000

Auditee qualified as low-risk auditee? X Yes No

Section II – Financial Statement Findings

No findings were noted.

Baylor College of Medicine

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs

Finding 2021-001 Special Tests and Provisions – Gramm-Leach-Bliley Act – Student Information Security

Identification of the federal program:

U.S. Department of Education (ED)
Office of Federal Student Aid
SFA Cluster
Assistance Listing Nos. 84.033, 84.038, 84.268

Criteria or specific requirement (including statutory, regulatory or other citation):

2 CFR 200.303 requires that a non-federal entity must “(a) establish and maintain effective internal control over the Federal award that provides reasonable assurance that the non-Federal entity is managing the Federal award in compliance with Federal statutes, regulations, and the terms and conditions of the Federal award. These internal controls should be in compliance with guidance in “Standards for Internal Control in the Federal Government” issued by the Comptroller General of the United States and the “Internal Control Integrated Framework”, issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).”

16 CFR 314.4(b) requires institutions to “Identify reasonably foreseeable internal and external risks to the security, confidentiality, and integrity of customer information that could result in the unauthorized disclosure, misuse, alteration, destruction or other compromise of such information, and assess the sufficiency of any safeguards in place to control these risks. At a minimum, such a risk assessment should include consideration of risks in each relevant area of your operations, including: (1) Employee training and management; (2) Information systems, including network and software design, as well as information processing, storage, transmission and disposal; and (3) Detecting, preventing and responding to attacks, intrusions, or other systems failures.”

Baylor College of Medicine

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs (continued)

Criteria or specific requirement (including statutory, regulatory or other citation) (continued):	16 CFR 314.4(c) requires institutions to “Design and implement information safeguards to control the risks you identify through risk assessment, and regularly test or otherwise monitor the effectiveness of the safeguards’ key controls, systems, and procedures.”
Condition:	Baylor College of Medicine did not perform a risk assessment that addressed the three required areas as noted in 16 CFR 314.4(b) and, as a result, did not document safeguards in response to identified risks as required by 16 CFR 314.4(c). Further, Baylor College of Medicine did not have internal controls in place over GLBA requirements for the fiscal year ended June 30, 2021 (FY 2021).
Questioned costs:	\$0
Context:	Total federal expenditures for the SFA Cluster were \$21.7 million, of which \$21.3 million was from ED, for the year ended June 30, 2021, representing 5% of total federal expenditures.
Effect:	If risk assessments are not performed in accordance with GLBA requirements, internal and external risks to the security, confidentiality, and integrity of customer information that could result in the unauthorized disclosure, misuse, alteration, destruction, or other compromise of such information may occur.
Cause:	Baylor College of Medicine did not have policies and procedures addressing the requirements of 16 CFR 314.4(b) and (c).
Identification as a repeat finding, if applicable:	N/A

Baylor College of Medicine

Schedule of Findings and Questioned Costs (continued)

Section III – Federal Award Findings and Questioned Costs (continued)

Recommendation:

We recommend Baylor College of Medicine perform the required risk assessment and document and implement safeguards responding to identified risks annually. Management should implement policies and procedures, including internal controls, to ensure that Baylor College of Medicine is in compliance with the GLBA requirements, 16 CFR 314.4(b) and (c). Management should review the annual updates of risk assessments and documented safeguards and retain evidence of the review and approval.

Views of responsible officials:

Management agrees with the finding and has developed a plan to correct the finding.

EY | Building a better working world

EY exists to build a better working world, helping to create long-term value for clients, people and society and build trust in the capital markets.

Enabled by data and technology, diverse EY teams in over 150 countries provide trust through assurance and help clients grow, transform and operate.

Working across assurance, consulting, law, strategy, tax and transactions, EY teams ask better questions to find new answers for the complex issues facing our world today.

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation are available via ey.com/privacy. EY member firms do not practice law where prohibited by local laws. For more information about our organization, please visit ey.com.

Ernst & Young LLP is a client-serving member firm of Ernst & Young Global Limited operating in the US.

© 2022 Ernst & Young LLP.
All Rights Reserved.

ey.com